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Zusammenfassung 
 
Der Transkriptionsfaktor HOXA1 gehört zur Familie der Homeobox-Transkriptionsfaktoren, 
die eine wichtige Rolle in der Regulation der Morphogenese sowie während der Embryonal-
entwicklung einnehmen. Über die zugrundeliegenden Signalwege und Wirkungsmechanismen 
ist hingegen wenig bekannt. Die Expression von HOXA1 wurde im Zebrafisch hauptsächlich 
in vorne liegenden Regionen wie dem Kiemenbogen und im Gehirn nachgewiesen. Darüber 
hinaus konnte eine starke HOXA1 Expression in Brustkrebs Läsionen nachgewiesen werden. 
In dieser Arbeit wird gezeigt, dass HOXA1 in Endothelzellen exprimiert wird. In 
verschiedenen in vitro Assays konnte gezeigt werden, dass eine reduzierte HOXA1 
Expression in humanen Nabelschnur-Endothelzellen (HUVEC) zu einer verminderten 
Sprossung, Migration und Netzwerkbildung führt. Mittels Microarray Analyse von HOXA1 
defizienten HUVEC konnte E-Selektin als Zielgen identifiziert werden. E-Selektin ist ein 
Adhäsions-Molekül das in der Signaltransduktion involviert ist. Die Expression von E-
Selektin ist stark reduziert, was durch RT-PCR validiert wurde, indem gezeigt wurde, dass die 
E-Selektin Expression stark reduziert war, nachdem die Expression von HOXA1 mittels 
siRNA-Transfektion reduziert wurde. 
Um eine in vivo Relevanz zu zeigen wurden ebenfalls Experimente im Zebrafisch 
durchgeführt. Die reduzierte Expression von HOXA1 führte zu vaskulären Defekten sowohl 
in den Schwanzgefäßen als auch in den Kopfgefäßen. Des Weiteren zeigen die Zebrafische 
Kopfblutungen. 
In diesem Teil der Arbeit wurde somit die Bedeutung von HOXA1 für die Blutgefäßbildung 
gezeigt sowie eine regulatorische Beziehung zwischen HOXA1 und E-Selektin. 
Im zweiten Teil dieser Arbeit wird gezeigt, dass die Rho Kinasen ROCK I und II einen anti-
angiogenetischen Einfluss auf die Neovaskularisierung der Retina haben. Eine Isolektin-
färbung der Retina nach der Inhibierung von ROCK I und II mit pharmakologischen 
Inhibitoren zeigte ein dichteres vaskuläres Netzwerk. 
Des Weiteren wurde eine Herzinfarktstudie durchgeführt, in der ebenfalls ROCK I und II 
pharmakologisch inhibiert wurden. Diese Studie zeigte allerdings keine Unterschiede im 
Hinblick auf Prozesse der Angiogenese. 
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Summary 
 
The transcription factor HOXA1 belongs to the family of homeobox transcription factors, 
which takes up an important role in the regulation of morphogenesis as well as during 
embryonic development. The underlying signaling pathways and mechanisms are relatively 
unknown. The expression of HOXA1 in zebrafish was reported mainly in anterior regions like 
in the pharyngeal arch and brain regions. Moreover a high HOXA1 expression was 
demonstrated in breast cancer lesions.   
It is shown in this thesis that HOXA1 is expressed in endothelial cells. It was demonstrated in 
different in vitro assays that a reduced HOXA1 expression in human umbilical vein 
endothelial cells (HUVEC) leads to reduced sprouting, migration and network formation. 
A microarray analysis with HOXA1 deficient HUVEC identified E-selectin as a target gene. 
E-selectin is an adhesion molecule which is involved in signal transduction processes. The 
expression of E-selectin was highly reduced and this was validated with RT-PCR, which 
showed that the expression of E-selectin was strongly reduced after the expression of HOXA1 
was reduced using siRNA transfection. 
To show in vivo relevance additional experiments in zebrafish were done. A reduced HOXA1 
expression led to vascular defects in the trunk vasculature as well as in the head vasculature. 
Furthermore the zebrafish show head bleeding. 
Thus in this part of the thesis a relevance of HOXA1 for the formation of the vasculature was 
shown as well as a regulatory relationship between HOXA1 and E-selectin. 
In the second part of this thesis it was shown that the Rho kinases ROCK I and II have an 
anti-angiogenic influence on the neovascularization of the retina. Isolectin staining of the 
retina after ROCK I and II inhibition with pharmacological inhibitors showed a more compact 
vascular network. 
Furthermore a myocardial infarction study was performed in which also ROCK I and II were 
inhibited pharmacological. This study shows no difference with regard to angiogenesis. 
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1. Introduction 
 
1.1. The development of the vascular system 
 
The first organ system that is developed during embryogenesis is the vascular system. It is 
important to supply the developing embryo with nutrients, fluids and signalling molecules 
(Adams and Alitalo, 2007). At the beginning of development the embryo obtains oxygen and 
nutrients through diffusion because the organism is small and oxygen is able to diffuse across 
short distances of about 100 – 200 µm. However if the embryo grows, it becomes harder to 
maintain this supply and this requires the formation of the cardiovascular system. The 
cardiovascular system consists of blood cells, a complex vascular network and the heart (dela 
Paz and D’Amore, 2009). The development of the vascular system is subdivided into two 
major processes, called vasculogenesis and angiogenesis. Vasculogenesis is the de novo 
synthesis of blood vessels from endothelial cells, whereas angiogenesis stands for the growth 
of new blood vessels from pre-existing ones (Semenza, 2007). 
 
1.1.1. Vasculogenesis 
 
Blood vessels develop from angioblasts, also known as endothelial progenitor cells (EPCs). 
These endothelial progenitor cells differentiate from mesoderm cells just like hematopoietic 
progenitors, which are a link between the blood and the vascular systems. The same origin 
from EPCs and hematopoietic progenitors is important for angiogenesis throughout life. The 
EPCs aggregate to blood islands, fusing to assemble the primary vascular network of small 
capillaries; a process entitled vasculogenesis (Figure 1 and Adams and Alitalo, 2007; 
Carmeliet, 2005; Risau and Flamme, 1995). Angioblasts emerge to be induced by fibroblast 
growth factor (FGF) subsequently followed by assembly to the primary vascular network, 
which is achieved by cell migration and cohesion. Endothelial cell migration is additionally 
controlled by vascular endothelial growth factor (VEGF) (Poole et al., 2001). Following these 
formations of major vessels and the capillary plexus, development and maturation of the 
vascular system occur. This formation of blood vessels from pre-existing ones is called 
angiogenesis (1.1.2. and Figure 1). 
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Figure 1: Formation of the vascular network. Endothelial progenitor cells form a primitive vascular plexus 
(vasculogenesis) and the network expands by blood vessel formation of pre-existing ones (angiogenesis). The 
mature vascular network consists of veins, arteries and capillaries, by recruiting pericytes (PC) and smooth 
muscle cells (SMC). Lymph vessels can be formed by transdifferentiation from veins. Reprinted with permission 
from Macmillan Publishers Ltd: [Nature] (Carmeliet, 2005), copyright (2005). 
 
1.1.2. Angiogenesis 
 
The vascular plexus gradually expands by means of sprouting angiogenesis and non-sprouting 
angiogenesis. Sprouting angiogenesis is defined as the sprouting of capillaries from pre-
existing vessels, whereas non-sprouting angiogenesis, also called intussusception, is 
characterized by the splitting of already existing vessels along their longitudinal axis (Burri et 
al., 2004; Risau, 1997).  
Vessel sprouting is stimulated by growth factors like VEGF or FGF. These growth factors 
activate their receptors on the endothelial cells (ECs) of existing blood vessels. Then the ECs 
start with secretion of several proteases which degrade the vessel basement membrane. This 
results in a sprout and this sprout is guided by an EC at the tip of the sprout and therefore is 
called tip cell. The tip cell migrates toward the VEGF gradient (Gerhardt et al., 2003). This 
VEGF gradient is secreted from not vascular tissue. Behind the tip cell the ECs proliferate to 
form the capillary lumen. The cells which follow the tip cell are called stalk cells. Finally the 
phalanx cells and the stalk cells form the vascular lumen and a tight barrier. The phalanx cells 
extend only a few filopodia and migrate weakly in response to VEGF (Mazzone et al., 2009 
and Figure 2). 
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Figure 2: Sequenced steps of sprouting angiogenesis. (a) Sprouting starts with an initiation phase where 
nonvascularized cells deposit VEGF. (b) The endothelial cell near the highest concentration of VEGF becomes a 
tip cell. (c) The tip cell leads the sprout and the surrounding tissue invades by expanding filopodia. (d) The 
sprout elongates through proliferation of endothelial cells, called stalk cells. (e) Two tip cells fused to one vessel. 
(f) This formed vascular lumen leads to initiation of blood flow and tissue oxygenation reduces the VEGF levels. 
(g) To stabilize and mature the plexus recruit pericytes and form an extracellular matrix. (h) In the terminated 
vasculature the endothelial cells reconvert to a phalanx phenotype. Reprinted by permission from Macmillan 
Publishers Ltd: [Nature Reviews Clinical Oncology] (Carmeliet, 2009), copyright (2009). 
 
 
The other possibility in angiogenesis is splitting angiogenesis; referred to as intussusception. 
In this type of angiogenesis the capillary wall extends into the vascular lumen splitting a 
single vessel into two vessels. The intussusception process consists of four phases. First, two 
opposite capillary walls come into contact. Second, the EC junctions reorganize to allow 
growth factors and cells to invade into the vascular lumen. Third, an intrusion is formed at the 
area of contact and is filled with pericytes and myofibroblasts. These cells apply collagen 
fibres in order to make an extracellular matrix available. This extracellular matrix provides 
growth of the vessel lumen. The last phase is that the basal membrane and the ECs perforate 
in the centre and the newly formed vessels increase (Burri et al., 2004).  
The advantage of intussusception is that it is a reorganization of already existing cells. 
Therefore, intussusception makes it possible for an awesome number of new capillaries to 
grow without a corresponding increase of endothelial cells. This is especially important 
during embryonic development because there is not enough supply to form the vasculature 
with new cells. 
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1.1.3. Arteriogenesis 
 
Arteriogenesis adverts to an increase in the width of pre-existing arterial vessels. For this to 
occur EC channels become covered with smooth muscle cells (SMCs) and pericytes. The 
pericytes surround the vessel wall and promote maturation and quiescence of the vessel. 
Arteriogenesis is correlated to increased pressure resulting in an increase of radial wall stress 
and higher blood flow. These two events lead to an endothelial surface stress. The blood 
vessels enlarge in width and length until the stress factors are normalized (Prior et al., 2004). 
The process of arteriogenesis is associated with upregulation of cytokines and cell adhesion 
receptors. MCP-1 MMP, bFGF and TNF-α show increased levels caused by an intensification 
of shear stress. In short, MCP-1 is responsible for monocytes being able to attach to the cell 
wall. TNF-α offers an inflammatory milieu for the cells and bFGF induces mitosis in ECs. 
The last step is that MMPs alter the space around the arteries to make expansion possible 
(Van Royen et al., 2001). It is also known that nitric oxide is a factor in increasing vessel 
diameter as a response to increased flow (Tronc et al., 1996). 
 
1.1.4. Physiological and pathological angiogenesis 
 
Also in the adult organism angiogenesis occurs in a physiological and a pathophysiolocial 
way. Angiogenesis is important during the ovarian cycle and is induced in embryonic 
development (Augustin, 2005). Also in wound healing and tissue regeneration angiogenesis is 
an important factor to achieve healing (Carmeliet, 2005). 
Despite this, various pathological developments are known in which angiogenic progression 
plays an important role. In the case of a disordered balance between stimulators and 
inhibitors, angiogenesis becomes excessive. Many diseases are known to be affected by 
excessive angiogenesis; like asthma, cirrhosis, diabetes, obesity, multiple sclerosis, bacterial 
infections and autoimmune diseases (Carmeliet, 2005). In multiple sclerosis patients, the 
blood vessel density is increased in lesions (Holley et al., 2009).  
Also tumours induce angiogenesis at the point when the tumour reaches a dimension that is 
too large for oxygen diffusion. Tumours need a high amount of oxygen and nutrition and this 
can only be supplied by a formed tumour blood vessel network. Besides, the vascular system 
is also a circuit in which metastasis can crop up (Prager et al., 2011). 
In other diseases the angiogenic switch is insufficient and this causes a dysfunction of 
endothelial cells. Diseases occurring from insufficient angiogenesis are for example hyper-
tension, diabetes, atherosclerosis, stroke and Alzheimer’s disease (Carmeliet, 2005). 
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This described involvement of angiogenesis in various disease patterns leads to an immense 
interest in the development of anti-angiogenic pharmaceuticals. The most promising drug is 
Avastin which is an antibody against VEGF. Angiogenesis and also vasculogenesis can be 
inhibited with the selective binding of Avastin to VEGF. Avastin leads to a better survival of 
patients with tumours (Jain et al., 2006).  Worldwide 30% of deaths are caused by 
cardiovascular diseases and 13% caused by cancer (WHO, 2011), so it is important to do 
research on angiogenesis and find potential therapeutic targets.   
 
1.2. Angiogenesis regulation mechanisms  
 
It is very important to analyse the mechanisms that control blood vessel formation in order to 
understand the process of angiogenesis. The main regulators of angiogenesis are growth 
factors and their corresponding receptors, which activate the angiogenic signalling cascades 
(Carmeliet, 2003). Aside from migration processes; protein translation and folding, RNA 
metabolism, chromatin remodelling and very importantly transcriptional regulations (De Val 
et al., 2009) have been characterized as regulators for angiogenic processes.  
 
1.2.1. Hypoxia 
 
Many signals which lead to new blood vessel formation are a physiological response to 
hypoxia (Hadjipanayi et al., 2010). To guarantee a sufficient supply of oxygen hypoxia 
induces vessel growth. In the case of decreased oxygen levels in the tissue the transcription 
factor hypoxia inducible factor 1 (HIF-1) gets activated. HIF-1 further induces the expression 
of other different genes like VEGF or inducible nitric oxide synthase (iNOS). Also heme 
oxygenase 1 (HO1) is induced by HIF-1 and heme oxygenase 1 synthesizes the vasoactive 
molecules NO and CO (Kikuchi et al., 2005). So, one could say that HIF-1 promotes several 
processes in the field of angiogenesis like erythropoiesis and vasodilation (Semenza, 1998). 
Licht et al. showed in 2005 that the transgenic HIF-1-/- as well as the HIF-2-/- knock-out mice 
are embryonic lethal due to cardiovascular defects which indicates the important role of HIF. 
Taking all this into account, it would be a milestone in the therapy of cancer or ischemia if 
HIF activity could be manipulated either pharmalogically or with gene therapy approaches 
(Semenza, 2004). 
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1.2.2. Vascular guidance 
 
Angiogenesis is mainly driven by signalling cascades, which are often caused by ligand and 
receptor interactions. The most investigated signalling family is the VEGF family, which 
includes the neuropilins. Angiopoietins (Ang) with their receptors of the Tie family are also 
important. A third ligand-receptor family is the Eph-family with Eph Receptors and Ephrin 
Ligands. The netrins and SLITs are guidance cues which also play a role during angiogenesis. 
And finally the Delta-Notch signalling pathway has a key function in these processes. 
In general VEGF means the prototype of this gene family, VEGF-A. This family includes 
VEGF-A (Ferrara, 2002), VEGF-B (Olofsson et al., 1996), VEGF-C (Joukov et al., 1996), 
VEGF-D (Achen et al., 1998) and placenta growth factor (PIGF) (Maglione et al., 1991). The 
growth of vascular endothelial cells which derive from arteries and veins, is promoted by 
VEGF (Ferrara and Davis-Smyth, 1997). Several studies have investigated VEGF signalling 
in vitro as well as in vivo. VEGF is involved in all major angiogenic processes like sprouting, 
proliferation, migration and cell survival. VEGF binds to the two receptor tyrosine kinases 
VEGFR-1 (also Flt-1) and VEGFR-2 (also KDR, Flk-1) which are present at the surface of 
vascular endothelial cells (Vaisman et al., 1990). The importance of VEGF and its receptors 
in regulating angiogenesis are shown in transgenic mice. Flk-1-/- mice are embryonic lethal 
because of the absence of vasculogenesis and the inability to organize blood vessels (Shalaby 
et al., 1995). Additionally to the tyrosine kinase receptors, VEGF can also bind to neuropilin-
1 (NRP-1) and neuropilin-2 (NRP-2). Especially on the cell surface of different tumour cell 
lines NRP-1 and 2 are expressed and bind VEGF (Klagsbrun and Eichmann, 2005). The 
importance of NRP-1 for the development of the vascular system was shown in NRP-1 null 
mice. These mice die between embryonic day 10.5 and 14.5 caused by brain and vascular 
defects (Kawasaki et al., 1999). 
Following the VEGF-system, the second important vascular-specific ligand-receptor based 
system is the Ang-Tie signalling system (Suri et al., 1996). Tie1 and Tie2 are expressed by 
endothelial cells and hematopoietic stem cells (Partanen et al., 1992). Ang1 is expressed in 
several cell types, like pericytes, smooth muscle cells, fibroblasts and in some tumour cell 
lines (Stratman et al., 1998). It was shown that Tie1 expression is upregulated at sites of 
atherosclerotic plaques indicating that Tie1 plays a role in the regulation of ECs function in 
response to changes in flow (Porat et al., 2004). Observations in Ang1 or Tie2 deficient mice 
showed that these mice are able to form immature vessels during embryonic development, but 
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they fail to develop mature vessel because they cannot recruit pericytes (Thurston, 2003 and 
Yancopoulos et al., 2000). 
The largest sub-family of the receptor tyrosine kinases are the Eph receptors with its Ephrin 
ligands. They were identified to work as guidance cues in several developmental processes 
including cell migration, axonal outgrowth and angiogenesis (O’Leary and Wilkinson 1999). 
Eph-ephrin complexes regulate cell adhesion, leading to increased or decreased adhesion 
depending on the cell type and the Eph-ephrin complex. EphrinB2 and EphB4 deficient mice 
die around E10.5 due to impaired vascular differentiation (Wang et al., 1998 and Gerety et 
al., 1999). This verifies that EphB4-ephrinB2 is an important regulator of vascular morpho-
genesis. 
Further guidance cues, which were initially identified in the nervous system, are netrins and 
SLITs. Besides their function in the nervous system, there is evidence that they also are 
involved in angiogenesis. Netrins are expressed on endothelial cells and act through the 
receptor UNC5B. UNC5B is expressed on tip cells and UNC5B signalling leads to a re-
pulsion of the tip cell (Lu et al., 2004 and Wilson et al., 2006). Additionally, there is data 
existing that it also can promote angiogenesis (Epting et al., 2010). 
SLIT ligands and their corresponding ROBO receptors are known to play a role during neuro-
nal migration. In particular ROBO4 is a vascular specific receptor and is expressed on 
endothelial cells indicating an involvement during angiogenesis (Huminiecki et al., 2002). In 
2003 Wang et al. could show that recombinant SLIT2 induce migration and also tube 
formation in vitro. Additionally they found SLIT2 expression in many types of solid tumours. 
Bedell et al. (2005) investigate on ROBO4 expression in zebrafish and they discovered lace-
like intersomitic vessels (ISV) after ROBO4 knockdown and misdirecting ISV after ROBO4 
overexpression. ROBO4 is abundantly expressed in endothelial cells of tumours and SLIT2 
inhibition blocks migration of endothelial cells by ERK/FAK (Seth et al., 2005). 
The last example that should be mentioned here is the angiogenic ligand-receptor system 
Dll4-Notch. Inhibition or blocking of the Notch pathway results in an uncontrolled 
hypersprouting (Siekmann and Lawson, 2007) indicating its involvement in angiogenic 
processes. Arterial-venous differentiation is also Notch signalling dependent (Lawson et al., 
2001). The Delta/Notch system regulates the communication between the tip cells and the 
stalk cells and thereby this system promotes the sprouting activity (Hofmann and Iruela-
Arispe, 2007). The regulation of the Notch pathway is partially coupled to the VEGF 
pathyway (Lobov et al., 2007). 
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1.2.3. Transcriptional regulation in angiogenic processes 
 
In 1.2.2. it is shown how angiogenesis is regulated on the level of ligand-receptor signalling. 
But what about the remaining questions; like the gene expression downstream of those 
signalling pathways and also the regulation of receptor and ligand expression, about which 
still so little is known? The approach of investigating transcriptional regulation could provide 
some answers.  
A few transcription factors regulating endothelial cell development have been identified, for 
example Ets, Forkhead (FOX), GATA, Krüppel-like and Sox. All these transcription factor 
families indicate an involvement in vasculogenesis and angiogenesis (Figure 3). 
 
Figure 3: Transcription factors involved in endothelial development. This scheme shows the development 
from mesodermal progenitors to a primitive vasculature which develops into the arterial, venous and lymphatic 
endothelium. The transcription factors that are known to be involved in these processes are registered. Reprinted 
by permission from Elsevier [Developmental Cell] (De Val et al., 2009), copyright (2009). 
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The transcription factors of the Ets family play a role in endothelial gene expression. Some 
Ets family members are expressed very early in embryogenesis and in haemangioblasts 
(Patterson and Patient, 2006). Pham et al. (2007) silenced 4 Ets using a morpholino injection 
on zebrafish and found out that a combinatorial network of Ets factors are important to form a 
physiological vascular network. Inhibition of all 4 Ets genes resulted in a total loss of 
endothelial differentiation (Pham et al., 2007). 
The most investigated regulators of endothelial transcription are the members of the Forkhead 
(Fox) family. They are expressed in endothelial cells as well as in their precursors, so-called 
endothelial progenitor cells. Indeed the expression is not specific to ECs and their precursors 
although they play an important role in endothelial transcription and vascular development. 
Key players are the members of the FoxC, FoxF, FoxH and FoxO subfamilies (Papanicolaou 
et al., 2008). 
FoxC1 and FoxC2 are essential for vascular development indicated by data obtained from 
FoxC1-/- and FocC2-/- mice. These FoxC deficient mice showed many vascular defects (Kume 
et al., 2001). Additionally, these two FoxC proteins are involved in arterial and lymphatic EC 
differentiation. And there are some indicators that FoxC1 and FoxC2 are downstream 
effectors of the Notch signalling pathway (Hayashi and Kume, 2008 and Seo et al., 2006). 
Inactivation of FoxF1 also leads to a severe vascular phenotype resulting in embryonic 
lethality. This phenotype includes for example the absence of vasculatization in the allantois 
as well as in the yolk sac (Mahlapuu et al., 2001). On the other hand, FoxH1 is known to play 
an inhibitory role in vascular development because FoxH1 overexpression in zebrafish leads 
to an impaired vascular system (Choi et al., 2007). 
It is clear that FoxO1 is important during vascular development, but up until now the 
mechanism behind is unclear. Interestingly, it is know that FoxO1 can act as a positive 
regulator of transcription as well as a negative regulator, indicating that FoxO1 may function 
as a transcriptional switch in the endothelium (Daly et al., 2004 and Paik et al., 2007). 
GATA2 is a zinc finger transcription factor which is an important regulator of endothelial 
genes (Lee et al., 1991 and de Val et al., 2009) since many endothelial enhancers include 
GATA binding sites. 
Krüppel-like factor (KLF) transcription factors function in EC after differentiation and 
specification. This was shown amongst others by Kuo et al. (1997) where they observed death 
of KLF2-/- mice on E14.5 due to incorrect vessel stabilization.  
Sox transcription factors like Sox7, Sox17 and Sox18 are known to be needed for 
arteriovenous specification. Knockdown of Sox7 and Sox18 in zebrafish leads to vascular 
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defects (Cermenati et al., 2008). This vascular phenotype consists of fusions between the 
major axial vessels, errors in arteriovenous specification and the lack of trunk and tail 
circulation. 
Additionally, the transcription factors of the HOX family are important during angiogenesis 
and vasculogenesis as described in the next section. 
 
1.3. The family of Homeobox transcription factors 
 
Homeobox (HOX) genes encode transcription factors. They are known to regulate cell 
proliferation and migration. HOX genes play an important role in the development of the 
cardiovascular system during embryogenesis. During embryogenesis the HOX genes are 
important regulators to develop and form the anterior-posterior axis. Beside this function 
HOX genes are needed during the development of body patterns and organogenesis (Gorski 
and Walsh, 2000). Some HOX genes are oncogenes and thus they play a role in tumour 
development (Sha und Sukumar, 2010). Many HOX genes play also a role in angiogenesis 
which will be discussed in 1.3.1. The regulatory mechanisms of HOX gene expression are 
only partly understood. It is known that HOX expression can be induced by retinoic acid, 
FGF and steroid hormones (Svingen and Tonissen, 2006). 
 
Figure 4: HOX genes in the human and zebrafish species. The characters indicate the cluster and the number 
the position in the anterior-posterior axis. Gene duplication in the zebrafish genome leads to a higher number of 
HOX genes in the zebrafish. Adapted and modified by permission from Ivyspring International Publisher 
[International journal of biological science] (Monteiro et al., 2006), copyright (2006). 
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All HOX genes share a 183 base-pair respectively 61 amino-acid DNA-binding domain called 
a homeobox. This homeobox contains of a helix-turn-helix motif which can interact with 
DNA (Cantile et al., 2008) The HOX-genes of mammals are organised in four clusters named 
A through D. Each cluster contains a maximum of 13 HOX genes named HOX1 through 
HOX13 and in combination with its cluster they are named HOXA1 through HOXD13. HOX 
genes with the same number share a high homology and not every number is present in every 
cluster (Figure 4; Monteiro et al., 2006). Because of gene duplications in the zebrafish more 
HOX genes are found in the zebrafish genome.  
1.3.1. The role of HOX-genes in angiogenesis 
 
In 1996 Miano et al. published for the first time that HOX-genes play a role in angiogenesis. 
They reported that HOXA5, HOXA11, HOXB1, HOXB7 and HOXC9 are expressed in 
human smooth muscle cells (SMC). These HOX-genes are able to distinguish between foetal 
and adult smooth muscle cells thereby modulating vascular functions (Figure 5). 
The paralogous HOX-genes HOXA3, HOXB3 and HOXD3 have overlapping as well as 
complementary roles during angiogenic processes (Cantile et al., 2008). In HOXA3-/- knock-
out mice cardiogenesis is impaired due to short or absent arteries (Chisaka et al., 2005). 
HOXB3 expression leads to an increased capillary morphogenesis whereas HOXD3 
overexpression generates haemangiomas (Boudreau et al., 1997 and Myers et al., 2000). 
Another important HOX-gene during angiogenesis is HOXA5. It had been shown that an 
“increased HOXA5 expression blocks angiogenesis in vivo and cell migration in vitro” 
(Rhoads et al., 2005). The anti-angiogenic effect resulted eventually from an interaction 
between HOXA5 and the vascular endothelial growth factor receptor-2 (VEGFR-2) as 
Coultas et al. suggested in 2005.  
HOXA9 is a regulator of angiogenesis by acting as a proinflammatory factor. HOXA9 
mediates cytokine induction of E-selectin (Bandyopadhyay et al., 2007) and is able to bind to 
the VEGFR-2 promoter and to the promoter of the endothelial nitric oxide synthase (eNOS) 
(Rössig, Urbich et al., 2005). Studies by the group of S. Dimmeler showed that 
overexpression of HOXA9 leads to a higher EphB4 gene expression (Bruhl et al., 2004). 
The last gene of the HOXA locus, namely HOXA13, interacts with EphA7 and EphA4 
(Stadler et al., 2001). 
The most investigated HOX locus is the HOXB locus, because 8 out of 10 HOXB genes are 
known to be expressed in human umbilical vein endothelial cells (HUVEC) indicating an 
important role during new blood vessel formation (Belotti et al., 1998). 
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HOXB2 induces inhibition of proliferation shown in in vitro studies in HUVEC by Liu et al. 
(2004). HOXB5 transactivates the VEGFR promoter (Wu et al., 2003) and HOXB7 can 
transactivate several pro-angiogenic factors for example FGF, CXCL1, Ang2 and MMP (Caré 
et al., 1996). 
Hemangioblast Angioblast mature endothelium primitive plexus                     mature vascular 
system
tumor angiogenic vessel                            vessel wall destabilization quiescent vessel
and endothelial cell proliferation
normal vasculogenesis
HOXB5 HOXD3 HOXA3
HOXB3
HOXD3
tumor angiogegensis
HOXB7
HOXA5
HOXD10
HOXA3
HOXA9
HOXA13
 
Figure 5: The role of HOX genes during normal and pathological vessel formation. At the top physiological 
vessel formation is shown. At the bottom pathological angiogenesis is illustrated. The HOX genes involved in 
those processes are shown in red (proangiogenic) and blue (antiangiogenic). Adapted and modified by 
permission from Elsevier: [Nutrition, Metabolism and Cardiovascular Diseases] (Cantile et al., 2008), copyright 
(2008). 
 
 
Loss of function of HOXC5 and the paralogous genes HOXA5 and HOXB5 leads to the 
formation of an additional pharyngeal arch containing an aortic arch artery. This novel aortic 
arch artery is completely independent and has a normal cardiac outflow (Kirby et al., 1997).  
HOXC9 is strongly expressed in quiescent endothelial cells and regulate vascular function via 
inhibition of Il-8. Otherwise HOXC9 is downregulated in active endothelial cells. And it was 
shown that HOXC9 is restrained under hypoxic conditions (Stoll et al., 2011). 
HOXD3 seems to be the most involved HOX-gene in angiogenesis. In addition to the function 
described above HOXD3, expression induces the production of collagen A1 and β3 integrin to 
enhance wound healing (Uyeno et al., 2001). Increased levels of angiogenic processes and 
cerebral blood flow are the result of ectopic HOXD3 expression in the mouse brain (Chen et 
al., 2004). HOXD3 is able to enhance the transcription of the integrin αvβ3 in endothelial cells 
(Boudreau et al., 2004). 
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Finally HOXD10 indicates an anti-angiogenic effect, resulting in blocked angiogenesis and 
migration in the endothelium and also in human breast cancer cells (Myers et al., 2002). 
1.3.2. The role of HOXA1 
 
In recent years many aspects of the role of HOXA1 were discussed. In 1991 Lufkin et al. 
showed for the first time that HOXA1-/- knock-out mice died shortly after birth due to anoxia 
and several other defects concerning delayed hindbrain neural tube closure, malformed inner 
ears and the absence of appointed cranial nerves and ganglia, whereas heterozygous mice 
developed normally and stayed alive. These findings were approved in 1992 by Chisaka et al., 
where they specified this phenotype. First they described an ear phenotype where they could 
show that both inner ear compartments were poorly developed in HOXA1-/- mice. Also the 
middle ear and the external ear were gravely affected in HOXA1-/- mice. This implies in detail 
that the formation of the cochlea and the vestibule were malformed, the cochlear and the 
vestibular nerves were totally absent (Figure 6A). Focusing on the external ear it was showed 
that the auricle as well as the external acoustic meatus is deformed. Additionally the 
homozygous HOXA1-/- mice showed defects concerning the cranial nerves. Moreover the 
glossopharyngeal ganglion (GIX) and the vagus ganglion (GX) are poorly developed which 
results in an absence of preganglionic connections with the brainstem. The ganglions VII/VIII 
(facial ganglion/vestibulocochlear ganglion) and the trigeminal ganglion (GV) are particularly 
displaced resulting in the fusion of these ganglions (Figure 6B). 
+/+ -/-+/- -/-
A B
 
Figure 6: Ear defects and malformed cranial nerves in HOXA1-/- mice. (A) Frontal sections of inner ear 
compartments of newborn mice show severe defects in the HOXA1 deficient mice (c,d). The inner ear of 
homozygous mice looks normal (a,b) (B) The ganglion IX and X are poorly developed in the HOXA1 deficient 
mice (c) in comparison to wildtype mice (a). GV and GVII/GVIII are displaced in the HOXA1 deficient mice 
which results in a fusion of these ganglions. Reprinted by permission from Macmillan Publishers Ltd: [Nature] 
(Chisaka et al., 1992), copyright (1992). 
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HOXA1 mutations in human individuals cause a broad spectrum of disease patterns. In 2005 
Tischfield et al. described homozygous truncating mutations in HOXA1 in different, 
genetically isolated, populations. In this study the authors observed five consanguineous 
families, four families from Saudi Arabia and one family from turkey. The defects in HOXA1 
are the reason for the Bosley-Salih-Alorainy syndrome (BSAS). This disease is characterized 
by horizontal gaze abnormalities (Figure 7A), facial weakness, deafness, mental retardation, 
autism spectrum disorder and hypoventilation. And this syndrome includes vascular 
malformations of the internal carotid arteries and cardiac outflow tract (Figure 7B).  
 
A B
a b c
 
Figure 7: Disease pattern of human individuals with HOXA1 mutations. (A) Horizontal gaze eye movement 
in a person affected with BSAS. (B) (a) Computed tomography of the temporal bone and the left inner ear with a 
normal developed cochlea, vestibule and lateral semicircular canal. (b) Computed tomography of the same area 
as in (a) of an individual with BSAS showing poorly developed inner ear and a cavity. (c) Computed 
tomography of the skull base with an absent left carotid canal. Reprinted by permission from Macmillan 
Publishers Ltd: [nature] (Tischfield et al., 2005), copyright (2005). 
 
In 1996 another syndrome which is called Athabaskan brainstem dysgenesis syndrome or 
Navajo brainstem syndrome was already described (Friedman et al.). This syndrome is also a 
result from mutations in HOXA1 and the disease pattern is similar to the BSAS. 
 
1.4. Selectins and their role in angiogenesis 
 
Three different selectins are known to be expressed in human individuals: E-selectin, P-
selectin and L-selectin. These selectins are adhesion molecules and are type-I transmembrane 
glycoproteins  which are expressed on leukocytes and cancer cells. Selectins  bind  to 
carbohydrate  ligands  in  a  calcium‐dependent  manner.  Selectins and their ligands are 
involved in signal transduction to regulate several cell functions.  
E-selectin is present in the plasma membrane of endothelial cells, P-selectin is expressed by 
endothelial cells and also by platelets and L-selectin is produced by leukocytes.  
E-selectin, also known as CD62-antigen-like family member E (CD62E), ELAM-1 or 
LECAM2, is a cell adhesion molecule, which is only expressed on endothelial cells, and is 
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activated by cytokines. E-selectin is encoded by the SELE gene. E-selectin has a C-type lectin 
domain on the amino-terminus, an EGF-like domain, six short consensus repeat domains, a 
transmembrane domain and a short cytoplasmic tail at the carboxy-terminus (Springer, 1994 
and Figure 8). Soluble E-selectin can be found in serum and plasma and is released by 
activated or damaged human endothelial cells (Leeuwenberg et al., 1992 and Pigott et al., 
1992). 
 
lectin domain
EGF- like domain
consensus repeats
transmembrane
domain
cytoplasmic tail
L-selectin E-selectin P-selectin
 
Figure 8: Structure of the three different selectins: L-selectin, E-selectin and P-selectin. All three selectins 
have a lectin domain (lavender) and an EGF-like domain (blue). L-selectin consists of two consensus repeat 
domains (green), E-selectin of six and P-selectin of nine. The transmembrane domain and the cytoplasmic tail at 
the carboxy terminus are identical in all three selectins. Adapted and modified from Hill, 2011. 
 
1.4.1. E-selectin and its regulatory factors 
 
Several transcription factors such as TNF-α, IL-1, NF-κB and activator protein 1 are known to 
regulate the transcription of E-selectin (Collins et al., 1995 and Higai et al., 2006). There exist 
four regulatory elements in the human E-selectin promoter, three NF-κB binding sites and one 
activation transcription factor (ATF) binding site (Kaszubska et al., 1993). The expression of 
E-selectin can be induced by shear stress, VEGF, high mobility group 1 B-box (HMGB1) and 
monocytes (Gaucher et al., 2007; Stannard et al., 2007; Treutiger et al., 2003; Rainger et al., 
1996). The activation of Rho family GTPases by different stimuli leads to an upregulation of 
E-selectin (Cernuda-Morollón et al., 2006). E-selectin expression through TNF- α stimulation 
is inhibited by IL-4 and STAT6, which antagonizes the binding of NF-κB (Bennett et al., 
1997). The expression of E-selectin can be blocked by inhibitors of transcription and 
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translation such as actinomycin D and chyclohexamide, cytokines, and glucocorticoids 
(Cronstein et al., 1992). 
1.4.2. Role of E-selectin in angiogenesis and tumour differentiation 
 
E-selectin plays an important role in several angiogenic processes and it is also involved in 
cancer metastasis. Possible functions of E-selectin in cardiovascular diseases, like diabetes 
and hypertension, were reported (Roldán et al., 2003). In patients with these disease patterns 
the expression level of E-selectin is higher than in healthy persons. Increased levels of E-
selectin were also found in patients with acute ischemic stroke (Fassbender et al., 1995). 
During inflammation E-selectin is responsible for the recruitment of leukocytes to the place of 
injury. The cytokines IL-1 and TNF in the area of wounded cells induces the overexpression 
of E-selectin on endothelial cells of blood vessels near the site of injury (Jubeli et al., 2011).  
In the case of an enhanced blood glucose level, for example during sepsis, the expression of 
E-selectin is higher which results in a higher microvascular permeability. This higher 
permeability causes edema resulting in skeletal muscle ischemia and finally necrosis (Visser 
et al., 2006). 
Selectins regulate the extravasation of tumour cells and the selectin ligands are involved in 
cancer metastasis. In patients of colorectal cancer E-selectin was detected in endothelial cells 
nearby cancer nodules (Kiriyama et al., 1995). In gastric cancer, especially in highly 
vascularised tumour areas, de novo expression of E-selectin was found (Mayer et al., 1998). 
Moreover, E-selectin expression is significantly higher in malignancies tumours than in 
benign tumours of head, neck and breast cancer (Renkonen et al., 1999 and Nguyen et al., 
1997). 
The adhesion of cultured human epithelial cancer cell lines of the pancreas, lung, liver and 
colon origin on the endothelium, occurs in an E-selectin-dependent pathway (Takada et al., 
1993). 
E-selectin-deficient mice are viable and showed no obvious developmental defects. These 
knock-out mice show no changes “in the trafficking of neutrophils in models of 
inflammation” (Labow et al., 1994). Furthermore the study of Labow et al. showed that E-
selectin and P-selectin are functionally redundant and it seems that a functional neutrophil 
migration needs an endothelial selectin either P-selectin or E-selectin. 
The development of pharmaceuticals that can inhibit the binding of E-selectin could disrupt 
the metastasis progression. The limitation of this strategy therein is that the selectins play an 
important role in several physiological processes. Furthermore the selectins interact with 
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many ligands as well as other adhesion molecules and all these interactions have to be 
considered when developing pharmaceuticals. In the past many clinical trials for treatment of 
diseases, such as arthritis, asthma and atherosclerosis were performed, but all these trials did 
not achieve successful results (Hill, 2011).  
Traditional Chinese herbal medicines such as berberin are known to downregulate E-selectin 
(Hu et al., 2009). 
1.5. Role of the RhoGTPases in angiogenesis 
 
Important regulators of many diverse developmental and cellular processes are the small 
guanosine triphosphatases (GTPases). The Rho/Rac family proteins are involved in cell 
division, cell proliferation, gene expression, apoptosis and transcription factor activity in 
normal conditions as well as during pathological ones (Bryan and D’Amore, 2007). At 
present 23 members of the RhoGTPases have been identified and some proteins like RhoA, 
Rac1 and Cdc42 have been extensively characterized (Bustelo et al., 2007). Several studies 
have implicated in the last years that RhoA-GTPases are involved in the regulation of several 
angiogenic processes for example proliferation, migration, morphogenesis and vascular 
permeability. And they were identified as downstream effectors of VEGF signalling. The 
majority of these proteins behave as “molecular switchers” which means that they fluctuate 
between an inactive and an active state. The conformations depend on the binding of either 
GDP or GTP to the protein. This cycle is controlled by guanosine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs) (Beckers et al., 2010; Rossman et al., 2005 
and Tcherkezian et al., 2007). 
1.5.1. Cellular functions of ROCK I/II 
 
The Rho kinases I and II referred to as ROCK I and II, are protein serine/threonine kinases of 
around 160 kDa. Two isoforms exists: ROCK I and ROCK II. Both ROCK I and ROCK II are 
ubiquitously expressed across human, rat and mouse tissues. ROCK I is more prominent in 
the liver, testis and kidney, whereas ROCK II is more pronounced in the brain and in skeletal 
muscle. Both ROCK I and ROCK II are expressed in vascular smooth muscle and in the heart. 
These kinases consist of an amino-terminal kinase domain, a potential coiled-coil-forming 
region including the Rho-binding domain (RBD), a pleckstrin homology (PH) domain, which 
has an internal cysteine-rich domain (Figure 9A). The amino-acid sequences of the two 
ROCK isoforms have 65% overall identity, and they share 92% identity in their kinase 
domains (Riento and Ridley, 2003). In the inactive form, the PH domain and the RBD of 
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ROCK bind to the amino-terminal region of the protein, which forms an autoinhibitory loop. 
Activated, GTP-bound Rho binds to RBD of ROCK, which results in an open conformation 
of the kinase and sets the catalytic activity free. Additionally, ROCK can be set in motion by 
arachidonic acid, which binds to the PH domain of ROCK, which also results in an open 
conformation of the kinase. The isoform ROCK I can also be activated by caspase-3-mediated 
cleavage next to the carboxyl terminus (Figure 9B). 
 
Figure 9: Structure and regulation of ROCK I and II. (A) ROCK I/II consist of a kinase domain at the amino 
terminus, a Rho binding domain (RBD) and a pleckstrin homology (PH) domain including a cysteine rich 
domain (CRD). (B) Inactive ROCK forms an autoinhibitory loop by binding of RBD and PH to the kinase 
domain (left). ROCK can be activated via three possible scenarios: GTB-bound Rho binds to RBD, arachidonic 
acid bind to PH or caspase-3 slice near the carboxyl terminus. Adapted and modified by permission from 
Macmillan Publishers Ltd: [Nature Reviews Molecular Cell Biology] (Riento and Ridley, 2003), copyright 
(2003). 
 
 
ROCKs phosphorylate several substrates leading to various cellular responses (Figure 10). 
ROCK phosphorylates ERM (ezrin-radixin-moesin) and these proteins are responsible for 
actin-membrane linkage. Phosphorylated LIM (Lin11, Isl1 and Mec3) kinase is responsible 
for actin-filament stabilization through cofilin inhibition. MLCP (myosin light chain 
phosphatase) is responsible for the dephosphorylation of MLC (myosin light chain), and so 
negatively controls actomyosin-based contractility (Riento and Ridley, 2003). 
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Figure 10: ROCK targets with their contribution in cellular functions. GTP-bound Rho subsequently 
activates ROCK and activated ROCK leads to phosphorylation of several target genes. Adapted and modified by 
permission from Macmillan Publishers Ltd: [Nature Reviews Molecular Cell Biology] (Riento and Ridley, 
2003), copyright (2003). 
 
 
The inhibitors used to investigate ROCK function are not specific for the isoforms ROCK I 
and II. But in vivo studies with ROCK I or ROCK II deficient mice showed that the isoforms 
have different functions because their phenotypes are altered. ROCK I-/- mice showed an 
omphalocele phenotype caused by a disorganization of actin filament in the epithelial cells of 
the umbilical ring. Also due to disorganized actin filament in the eyelid the mice display 
eyelid open at birth (Shimizu et al., 2005). ROCK II-/- mice are embryonic lethal and this       
is caused by a dysfunction of the placenta. Additionally the intrauterine are strongly growth 
retarded caused by thrombus formation in the placenta (Thumkeo et al., 2003). This      
ROCK II-/- phenotype indicates that the loss of ROCK II cannot be compensated by ROCK I. 
 
1.5.2. ROCKs and their vascular and cardiovascular functions 
 
A lot of investigation was done to develop inhibitors for Rho kinases ROCK I and II, gaining 
new treatment options for cardiovascular disorders such as hypertension and ischemic stroke 
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(Shimokawa et al., 2007). Several in vitro and in vivo studies showed that inhibition of ROCK 
I and II provide a strategy to inhibit angiogenesis (Hata et al., 2008; Pang et al., 2009; Uchida 
et al., 2000). On the other hand, our group was able to show that inhibition of Rho kinases 
with H1152 promotes angiogenesis in vitro. ROCK inhibition activates VEGF-induced 
sprouting of endothelial cells and increases VEGF-induced angiogenic signalling (Kroll et al., 
2009). It was also shown that inhibition of Rho kinases improves the function of the 
endothelium in patients with coronary artery disease (Nohria et al., 2006). These two different 
findings suggest a dual role of Rho kinases during angiogenesis. Van Hinsbergh and van 
Nieuw Amerongen tried to bring these opposite effects together. They proposed a model that 
ROCK I and II can promote cortical tension and tail retraction. Cortical tension leads to less 
branching and finally inhibits or blocks angiogenesis. Tail retraction on the other hand leads 
to more sprouting and thereby more angiogenesis (van Nieuw Amerongen and van Hinsbergh, 
2009). 
 
1.6. Aim of the thesis 
 
To understand the complex mechanisms behind blood vessel formation and function it is very 
important to comprehend the transcriptional regulation of angiogenesis (see also 1.2.3.). As 
stated earlier several transcription factors have been described as regulators of angiogenic 
processes. Certainly, the knowledge regarding their precise mechanisms is not fully 
understood. The transcription factor HOXA1 is highly conserved between the human, mouse 
and zebrafish genomes. Studies about HOXA1 mutations in human individuals indicate a 
possible function of HOXA1 during angiogenesis (1.3.2.). Sprouting and migration are 
influenced by HOXA1. 
This work was aimed to characterize the function of HOXA1 in angiogenesis and the 
involvement of HOXA1 in the regulatory mechanisms of angiogenesis. To answer these 
questions in vivo studies in zebrafish were performed and several in vitro angiogenesis assays 
were performed to characterize the function of HOXA1 in cultured human umbilical vein 
endothelial cells (HUVECs). Finally a microarray analysis was arranged to find potential 
target genes of HOXA1.  
 
A second part of my PhD thesis was to contribute to the very controversial issue of whether 
the Rho kinases I and II (ROCK I/II) are pro- or anti-angiogenic. Previous studies from our 
group showed that the inhibition of ROCK I and II leads to higher neovascularisation in 
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mouse retina and to more sprouting in HUVECs (Kroll et al., 2009). For the investigation of 
its endothelial function, both kinases were pharmacologically inhibited in this thesis with the 
specific inhibitor H-1152 and the unspecific inhibitors Fasudil and Y-27632. An OIR-study 
was performed to investigate the retinal neovascularisation and a myocardial infarction study 
focused on the involvement of ROCK I and II in heart regeneration.  
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2. Material and Methods 
2.1. Material 
2.1.1. Equipment 
 
A1R confocal laser scanning system   Nikon 
Agarose gel documentation system   Intas 
Analytical balance (ABS)     Kern 
Blotting chamber     Peqlab 
Boyden chamber     Neuro Probe 
C1-CLEM confocal laser scanning system  Nikon 
Cell counting chamber    Neolab 
Centrifuge (Rotina™ 420R)     Hettich 
Chemiluminescence-imaging system   Peqlab  
CO2 cell culture incubator (HERA cell 150®)  Thermo Scientific 
Confocal microscope DMIRE2 (TCS SP2)  Leica 
PCR Cycler      Bio-Rad 
Electrophoresis chamber    Peqlab 
Electrophoresis power supply   Consort 
Fluorescence microscope Axio Imager 2  Zeiss 
Fluorescence microscope DMI 6000 B  Leica 
Incubation shaker (CERTOMAT®IS)  Sartorius 
Incubator      Memmert 
Inverted light microscope Type 090-135.001 Leica 
Microbiological Safety Cabinets (HERAsafe®)  Thermo Scientific 
Microcentrifuge (Mikro™ 200R)    Hettich 
Minicentrifuge (Rotilabo® Uni-fuge)   Carl Roth 
Olympus IX50 microscope    Olympus 
Pipets       Gilson 
Photometer      Eppendorf 
Precision balance (PC2200)     Mettler 
Rocking shaker      Neolab  
Thermo Mixer (MHR11)     HLC BioTech 
Water bath      Julabo 
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2.1.2. Chemicals 
 
All chemicals that are used in the described experiments – as not indicated otherwise – were 
purchased from the following companies: 
 
AppliChem GmbH 
Carl Roth GmbH 
Fermentas GmbH 
Merck AG  
Roche Diagnostics GmbH 
Sigma Aldrich Chemie GmbH 
2.1.3. Animals 
2.1.3.1. Zebrafish lines 
 
For all experiments the AB wildtype line, the tg(fli1:EGFP) line (Lawson and Weinstein, 
2002) and the tg(fli1:EGFP/tg(gata1:dsRed) line were used. 
2.1.3.2. Mouse 
 
C57BL/6 wildtype line     Harlan Winkelmann GmbH 
2.1.3.3. Rat 
 
Male wistar rats       Harlan Laboratories, Netherlands 
 
2.1.4. Morpholinos 
 
The Morpholinos were obtained from GeneTools, LLC and the following morpholinos were 
used: 
 
HOXa1a-TB-Mo: 5’- CTAAGAATGTGCTCATTGTGTCATC -3’  
Standard Control-Mo (Co-Mo): 5’- CCTCTTACCTCAGTTACAATTTATA -3’ 
2.1.5. Inhibitors and growth factors 
 
Desferrioxamine mesylate (Dfx)    Sigma-Aldrich 
Fasudil (HA-1077)      LC Laboratories 
Fibroblast growth factor (FGF)    Relia Tech Cat 
H1152 dihydrochloride (ROCK I/II inhibitor)  Tocris Bioscience  
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Vascular endothelial growth factor (VEGF)   R&D Systems  
Y-27632 dihydrochloride     Tocris Bioscience 
2.1.6. Plasmids 
 
HOXA1 in pDONR221     DKFZ core facility 
pAd/CMV/V5-DEST      Invitrogen 
2.1.7. Bacteria 
 
MAX Efficiency® DH5α™ Competent Cells  Invitrogen    
MAX Efficiency® Stbl2™ Competent Cells  Invitrogen 
One Shot® Stbl3™ Chemically Competent E. coli  Invitrogen 
One Shot® TOP10 Chemically Competent E. coli  Invitrogen 
2.1.8. RT-PCR and PCR 
2.1.8.1. Reagents, buffers, nucleotides 
 
BufferS       Peqlab 
dNTPs (100 pmol)      Peqlab 
Taq-Polymerase      Peqlab 
2.1.8.2. Primer 
 
All primers were purchased from MWG (www.mwg-biotech.com) 
 
target gene   species sequence                                       
 
HOXA1  human  5’ CCC ATG GAG GAA GTG AGA AA 3’ 
     5’ CGC GTC AGG TAC TTG TTG AA 3’ 
 
HOXa1a  zebrafish 5’ ATG AGC ACA TTC TTA GAT TTT TCG 3’ 
     5’ TTA ATT AGA GGA GTA TGC CTC AAC A 3’ 
 
Actin   human  5’ GGC ATC CTC ACC CTG AAG TA 3’ 
     5’ GGG GTG TTG AAG GTC TCA AA 3’ 
 
Actin    zebrafish 5’ CTT GCG GTA TCC ACG AGA 3’ 
     5’ GCG CCA TAC AGA GCA GAA 3’ 
 
E-selectin  human  5’ AGC CCA GAG CCT TCA GTG TA 3’ 
     5’ CCT TTT GGA TCC CTT CAA CA 3’ 
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T7 long  human  5’ CGTAATACGACTCACTATAGGG 3’ 
 
pENTR forward  human  5’ TGGCCTTTTTGCGTTTCTAC 3’ 
 
 
2.1.9. Kits 
 
Caspase-Glo® 3/7 Assay System    Promega 
Illustra plasmidPrep Mini Spin Kit    GE Healthcare 
RNeasy       Qiagen 
SuperScript®First-Strand Synthesis System for RT-PCR Invitrogen 
Wizard® SV Gel and PCR Clean-Up System  Promega 
ABC Vectastain Kit      Vector Laboratories 
2.1.10. Cell culture 
2.1.10.1. Cells 
 
293A cells Invitrogen 
 
HUVEC (human umbilical vein endothelial Umbilical cords were obtained 
cells) from the Universitätsklinikum 
Mannheim and freshly isolated  
 
BAEC (bovine aortic endothelial cells) Invitrogen  
 
2.1.10.2. Media and reagents 
 
Collagen type I      isolated from rat tails 
Chemotaxis collagen      Sigma 
Dulbecco’s Modified Eagel’s Medium (DMEM)  Gibco 
Endothelial Cell Growth medium (ECGM)   Promocell  
Endothelial Cell Basal Medium    Promocell 
Fibronectin       Sigma-Aldrich 
Foetal Calf Serum (FCS)     Biochrom 
Matrigel       BD Bioscience 
Medium 199       Sigma-Aldrich 
Methylcellulose (Methocel)     Sigma-Aldrich 
OPTI-MEM       Gibco 
Penicillin-Streptomycin (P/S)    Invitrogen 
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Phosphate buffered saline (PBS)    Gibco 
Trypsin-EDTA      Gibco 
2.1.10.3. Transfection reagents 
 
Oligofectamin       Invitrogen 
 
2.1.10.4. Small interfering RNA (siRNA) 
 
HOXA1 siRNA (ID: 114539)    Ambion 
(sense: 5’ CCAUAGGAUUACAACUUUCtt 3’ ;  
antisense: 5’ GAAAGUUGUAAUCCUAUGGtc 3’) 
 
HOXA1 siRNA (ID: 3467)     Ambion 
(sense: 5’ GGAAUCCUCAGAGAAGUCCtt 3’ ;  
antisense: 5’GGACUUCUCUGAGGAUUCCtc 3’) 
 
non-targeting negative control 1 siRNA (AM4635)  Ambion 
 
In this thesis the siRNA with ID 114539 is called siHOXA1_A and the siRNA with ID 3467 
siHOXA1_B. 
 
2.1.10.5. Consumables 
 
Cell scraper (28 cm)      Greiner 
Conical tubes (15 and 50 ml)     Falcon 
Petri dishes (10cm, round)     Greiner 
Petri dishes (12 cm, quadratic)    Greiner 
Reaction tubes (0.5, 1.5 and 2 ml)    Eppendorf 
Serological pipettes (50, 25, 10 and 5 ml)   Greiner 
T75 flask       Greiner 
Tissue culture plates (96-, 48-, 24-, 6-well)   Greiner 
2.1.11. Antibodies 
2.1.11.1. Primary antibodies 
 
Goat-anti-human Actin (I-19)    Santa Cruz Biotechnology 
Goat-anti-human HoxA1 (AF5014)    R & D Systems 
Rabbit-anti-GFP (A-11122)     Invitrogen 
Isolectin B4 (L2895)      Sigma-Aldrich 
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2.1.11.2. Secondary antibodies 
 
Donkey-anti-goat Alexa 488 (A-11055)   Molecular Probes 
Rabbit-anti-goat Alexa 546 (A-21085)   Molecular Probes 
Rabbit-anti-goat HRP (P0160)    DAKO 
2.1.11.3. Nuclei staining 
 
DAPI B2883-25mg (stock: 10mg/ml)   Sigma-Aldrich 
 
2.1.11.4. Additional staining reagents 
 
DAB-tablet, 10mg      Sigma-Aldrich 
Fluorescent Mounting Medium    DAKO 
Hydrogen peroxide, 30%     Roth 
 
2.1.12. DNA and protein markers 
 
GeneRuler™ DNA Ladder Mix     Fermentas (SM0331)  
PagerRuler™ Protein Ladder     Fermentas (SM1811) 
 
2.1.13. Western Blot reagents 
 
Nitrocellulose membrane     Whatman 
ECL Western blot detection reagent    Thermo scientific 
 
2.1.14. Commercial enzymes and buffers 
 
Alkaline phosphatase CIP     New England Biolabs 
10x BSA       New England Biolabs 
Restriction buffers      New England Biolabs 
Restriction enzymes      New England Biolabs 
Proteinase K       Marcherey-Nagel 
Quick ligase       Takara 
Quick ligase buffer      Takara 
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2.1.15. Solutions and buffers 
 
10 x blotting buffer      30.28 g Tris 
106.6 g Glycine 
ad 1 l MilliQ water 
 
1 x blotting buffer      1 l 10x blotting buffer 
ad 10 l MilliQ water 
 
DAB/TrisHCl staining solution    1 ml 1 M Tris/HCl pH 7.4 
0.1% Tween20 
500 μl 10 mg/ml DAB solution 
ad 10 ml MilliQ water 
 
5 x DNA sample buffer  0.2% Bromphenol Blue solution 
(v/v)  
50% Glycerol (v/v)  
10 mM EDTA 
 
E3 (“eggwater”)      3 g Red Sea Salt 
ad 10 l MilliQ water 
 
10 x electrophoresis buffer     144 g Glycine 
30 g Tris 
10 g SDS 
ad 1 l MilliQ water 
 
1 x electrophoresis buffer     1 l 10 x electrophoresis buffer 
ad 10 l MilliQ water 
 
FACS buffer       0.5% FCS 
1 mM EDTA in PBS 
 
FACS washing buffer      2.5% FCS in PBS 
 
Giemsa       obtained from Sigma 
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LB agar       35 g LB-agar (Sigma) 
ad 1 l MilliQ water 
 
LB-Medium       20 g LB-Broth (Sigma) 
ad 1 l MilliQ water 
 
modified Ringer solution     116 mM NaCl 
2.9 mM KCl 
5 mM HEPES, pH 7.2 
 
NP-40 lysis buffer      150 mM NaCl  
50 mM Tris / HCl pH 7.4  
10 mM EDTA  
1% NP-40 (v/v)  
10% Glycerol (v/v)  
1% Protease Inhibitor Cocktail  
(Sigma-Aldrich) (v/v) 
 
10 x PBS       400 g NaCl 
10 g KCl 
57.5 g Na2HPO4 
10 g KH2PO4 
pH 6.8 
ad 5 l MilliQ water 
 
1 x PBS       1 l 10 x PBS + 9 l MilliQ water 
 
PBST        500 μl Tween 
ad 1 l 1x PBS 
 
PBSTT       500 μl Tween 
        500 μl Triton-X 
ad 1 l 1x PBS 
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4% PFA 16 g PFA dissolved in 400ml PBS 
while boiling and stirring, when 
dissolved cooled on ice 
 
10% PFA 40 g PFA dissolved in 400ml PBS 
while boiling and stirring, when 
dissolved cooled on ice 
 
5 x protein sample buffer      250 mM Tris / HCl, pH 6.8  
0.5 M DTT (1.4-Dithiothreitol)  
10% SDS (v/v)  
0.5% Bromphenol Blue solution 
(v/v)  
50% Glycerol (v/v) 
   
1-phenyl-2-thiourea (PTU, 5 x stock)   304 mg PTU 
ad 1 l MilliQ water 
        
Resolving gel solution (12% acrylamide)   6.4 mL Rotiphorese Gel 30 
4 mL 1.5 M Tris, pH 8.8 
5.32 mL MilliQ water  
160 μL 10 % SDS 
160 μL 10 % APS 
40 μL TEMED 
 
SOC medium       obtained from Invitrogen 
 
Soerensen A       9.08 g KH2PO4 
ad 1 l MilliQ water 
 
Soerensen B       11.8 g Na2HPO4  
        ad 1 l MilliQ water 
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Stacking gel solution      1.36 ml Rotiphorese Gel 30 
700 μl 1.5 M Tris, pH 6.8 
5.72 ml MilliQ water 
80 μl 10 % SDS 
80 μl 10 % APS 
20 μl TEMED 
 
Stripping solution      0.375 g Glycine  
500 μl fuming HCl  
ad 50 ml MilliQ water 
 
50 x TAE-buffer      400 mM Tris 
20 mM NaCH3COO 
10 mM Na2EDTA 
pH 7.8     
ad 1 l MilliQ water 
  
1 x TAE buffer      300 ml 50 x TAE buffer 
ad 5 l MilliQ water 
 
100mM TrisHCl buffer/Tween20    10 ml 1 M Tris/HCl pH 7.4 
10 μl Tween20 
ad 100 ml MilliQ water 
2.1.16. Miscellaneous 
 
Microscope glass slide     Thermo Scientific 
Microscope coverslip      Thermo Scientific 
Nucleopore Track-Etch Membrane    Whatman 
Nuclease free water      Ambion 
Microlance syringe      BD Bioscience 
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2.2. Methods 
2.2.1. Molecular biology 
2.2.1.1. RNA isolation 
 
The RNeasy kit from Qiagen was used for the RNA isolation. First the cells were washed with 
PBS and RLT buffer from the kit containing 10 µl/ml β-mercaptoethanol was used to lysate 
the cells. The cells were cultivated in 6-well plates and therefore 250 µl RLT buffer was used 
per well. For optimal decomposition the plates were frozen at -20°C or -80°C for minimal 30 
min up to three days. The plates were then thawed, scraped and transferred into reaction 
tubes. Then the lysates were treated according to the manufacturer´s instructions. Finally the 
RNA was eluted in 30 µl nuclease free water from the kit. 
The zebrafish embryos have to be dechorinated and deyolked by pipeting with a 200 µl pipet 
up and down. Then the embryos were centrifuged (5 min, 14000 rpm, 4°C) and resuspended 
in 600 µl (maximum of 60 embryos) RLT buffer from the kit containing 10 µl/ml β-
mercaptoethanol. For optimal decomposition the embryos were incubated on ice for 30 min 
on a rotation platform. To homogenize the embryos a BD microlance syringe (0.9 x 40 mm) 
were used. Then the lysates were treated according to the manufacturer´s instructions. Finally 
the RNA was eluted in 30 µl nuclease free water from the kit. 
To evaluate the quality and the concentration of the RNA, the concentration was measured 
with a photometer and 1% agarose gels (Sambrook and Russell, 2001) were performed. The 
RNA was stored at -80°C. 
 
2.2.1.2. Reverse transcription 
 
To produce first-strand cDNA 1 to 5 µg total cellular RNA was used. The transcription was 
performed according to the SuperScript®First-Strand Synthesis System instruction manual.  
The RNA was mixed with 1 µl Oligo(dT)12-18 Primer (0.5 µg/µl) and 1 µl dNTPmix (10 mM) 
and was adjusted to a total volume of 10 µl by adding DEPC-treated water. After incubation 
at 65°C for 5 min the probes were refrigerated on ice for one minute. Then the RT-reaction 
buffer was added: 2 μl 10x RT buffer, 4μl MgCl2 (25 mM), 2μl DTT (0.1 M) and 1 μl 
RNaseOUT recombinant ribonuclease inhibitor. After preincubation (42°C, 2 min) 1 µl 
SuperScript® II RT (50 U/µl) was added and incubated at 42°C for additional 50 min. The 
reverse transcription was stopped by heating to 70°C for 15min, followed by a 1 min on ice. 
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In a final step the RNA was digested by added 1 µl RNaseH (2 U/µl) and incubated for 20 
min at 37°C. The cDNA was stored at -20°C. 
 
2.2.1.3. Polymerase chain reaction (PCR) 
 
Polymerase chain reaction was accomplished using 2 µl cDNA, 2 µl Buffer S, 0.4 µl dNTPs, 
1 µl of sense and antisense Primer and 0.3 µl Taq-Polymerase. The total volume was 20 µl 
and was adjusted with deionised water.  
 
The amplification reaction was performed as follows: 
Initialization step  95°C, 2 min 
Denaturation   95°C, 30 min 
Annealing   primer dependent temperature, 30 sec 
Elongation   72°C, product size dependent time 
Final extension  72°C, 5 min 
 
For zebrafish Hoxa1a and zebrafish actin 33 cycles from denaturation to elongation were 
performed, for human HoxA1 35 cycles and for human actin 26 cycles. The annealing 
temperature for human HoxA1 and actin was 56°C and for zebrafish Hoxa1a and actin 54°C. 
The E-selectin PCR was done with 35 cycles and an annealing temperature of 57°C. The 
specific elongation time was 30 sec -1 min for all approaches. 
The PCR-product was stored at 8°C and a 1% agarose gel was performed to evaluate the 
result. 
 
2.2.1.4. Restriction of DNA and dephosphorylation of DNA-ends 
 
To clone DNA fragments in plasmids, restriction enzymes were used. In general up to 200 ng 
DNA were used for restriction in a total volume of 20 µl. The approach was: DNA, 2 µl 
buffer (type dependent on enzyme), 2 µl 1x BSA, 1 µl enzyme, ad 20 µl sterile water. For a 
higher amount of DNA, for a preparative restriction, the approach was: 3 µg DNA, 5 µl buffer 
(type dependent on enzyme), 5 µl 1x BSA, 1 µl enzyme, ad 50 µl sterile water. The 
restrictions were performed for 3 h in a water bath at 37°C. A 1% agarose gel was performed 
to evaluate the result. 
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To prevent the religation of the plasmids the DNA-ends were dephosphorylated. Therefore 1 
µl alkaline phosphatase CIP was added to the approach following by an additional incubation 
time for 30 min at 37°C. 
2.2.1.5. Gel electrophoresis 
 
The agarose gels were performed in a concentration of 1% agarose in TAE-buffer which were 
run at 100 V in TAE-buffer in an electrophoresis chamber. 
2.2.1.6. Extraction of DNA from agarose gels 
 
The Wizard® SV Gel and PCR Clean-Up System kit was used to extract DNA from the 
agarose gel. The desired fragments were cut out of the agarose gel with a scalpel and 
subsequently transferred in Membrane Binding Solution from the kit to dissolve the gel. 
According to the manufacturer´s instructions the extraction was performed and finally the 
respective DNA was eluted in 30 µl nuclease free water from the kit. 
2.2.1.7. Ligation and Transformation in E.coli 
 
To perform a ligation of DNA fragments into linearized plasmid the Quick ligase was used. 
To gain an optimal ligation result three times more insert-DNA fragments than linearized 
plasmids were used. To calculate the amount of DNA the following formula was applied: 
 
     (x) amount of plasmid [ng] x length of insert [kb]  
        x 3 = (y) amount of insert [ng] 
length of plasmid [kb] 
 
The amount of plasmid and insert (x and y) were adjusted with sterile water to a volume of 10 
µl. Then 10 µl of Quick ligase buffer and 1 µl Quick ligase was added. The complete ligation 
mix was incubated 30 min up to 5 h at 25°C or RT. 
The plasmids were transformed into E. coli to amplify the ligated plasmid. Different E. coli 
strains such as DH5α, stbl2, stbl3 and TOP10 were used. 50 µl of the respective E. coli stock 
were thawed on ice. 3 – 20 µl of the ligation approach were given to the E. coli, mixed with 
caution and left for 20 min on ice. Then the bacteria were treated with a heat-shock for 90 sec 
in a 42°C water bath and then the approach were immediately kept on ice for 2 min. In the 
next step 1 ml of SOC medium was added and the approach was incubated for 45 min in case 
of ampicillin resistance or 1 h in case of kanamycin resistance at 37°C and 200 rpm. After this 
incubation the bacteria were centrifuged 5 min and 6000 rpm and then 900 µl of the super-
natant was removed. The bacteria pellet were resuspended in the remaining supernatant and 
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plated on a LB-agar plate containing ampicillin (100 µg/ml) or kanamycin (25 µg/ml). The 
plates were incubated overnight at 37°C in an incubator. 
2.2.1.8. Isolation of plasmids from E.coli 
 
Single colonies from LB plates (see 2.2.1.7) were picked and transferred to a 3 ml culture 
composed of LB medium with ampicillin (100 μg/ml) or kanamycin (25 μg/ml).The cultures 
were incubated at 37°C and 200 rpm over night. The plasmids were isolated from this culture 
using the Illustra plasmidPrep Mini Spin Kit according to the manufacturer´s instructions. 
Finally the plasmid was eluted in 30 µl nuclease free water.  
2.2.1.9. Cloning procedures and adenovirus production 
 
The human HoxA1 full length clone in pDONR221 was cloned via gateway cloning into the 
pAd/CMV/V5-DEST vector using the gateway clonase from Invitrogen. The cloning step was 
verified via test restriction analysis and sequencing (performed by the DKFZ core facility). 
The adenovirus pAd-HoxA1 was produced using the ViraPower™ Adenoviral Expression 
System according to the manufacturer´s protocol from invitrogen. 
2.2.2. Biochemical analysis 
2.2.2.1. Extraction of protein lysates from HUVE cells and zebrafish 
 
To analyze the protein levels in vitro cells were washed with cooled PBS and the lysate was 
produced with NP-40 lysis buffer, 250 µl per 6-well were used. For optimal decomposition 
the plates were frozen at -20°C for minimal 30 min up to three days. The plates were then 
thawed, scraped and transferred into reaction tubes. Finally the lysates were centrifuged 5 min 
at full speed (14.000 rpm) at 4°C and the supernatant was transferred to a new reaction tube. 
To perform a SDS-PAGE 50 µl from this supernatant were mixed with 5 x Laemmli buffer 
and boiled 5 min at 95°C.  
 
To analyze the protein levels in zebrafish embryos first the embryos were dechorinated and 
deyolked by pipeting up and down with a 200 µl pipet. Normally 30 – 50 embryos per 
condition were used. After a centrifugation step for 5 min at full speed (14.000 rpm) at RT the 
embryos were resuspended in 100 µl NP-40 lysis buffer and then the embryos were incubated 
on ice on a rotating platform for 30 min. Then the embryos were homogenized with a BD 
microlance syringe (0.9 x 40 mm) and finally the lysates were centrifuged 5 min at full speed 
at 4°C. The supernatant was transferred into a new reaction tube and 50 µl from this 
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supernatant were mixed with 5 x Laemmli buffer to perform a SDS-PAGE. Finally the 
approach was boiled 5 min at 95°C. 
2.2.2.2. Western blot analysis 
 
Firstly the proteins were separated using a 12% SDS-PAGE, therefore an aliquot of the lysate 
was boiled with 5x Laemmli sample buffer for 10 min at 95°C. The proteins were transferred 
to a nitrocellulose membrane (2 h, 100 V) and blocked in 3% BSA for 1 h at RT on a rotating 
platform. The membrane was incubated with the primary antibody in a final concentration of 
1 µg/ml (solved in blocking solution) at 4°C overnight. After three times washing with PBST, 
the membrane was incubated with an HRP conjugated secondary antibody for 30 min and 
finally washed three times with PBST. The protein of interest was visualized by enhanced 
chemoluminescence (ECL reagent) and images were made with the Chemi-Capt 5000 
software. For a loading control actin was used and on that account the membrane has to be 
stripped. The membrane was incubated with the stripping solution for 30 min at RT on a 
rotating platform and subsequently washed three times with PBST. The actin antibody was 
used in a final concentration of 0,2 µg/ml (solved in PBST) and the membrane was incubated 
with this antibody for 2 h at RT on a rotating platform. After three times washing with PBST, 
the membrane was incubated with an HRP conjugated secondary antibody for 30 min and 
finally washed three times with PBST. Finally the protein was visualized by ECL reagent and 
Chemie-Capt 5000 software. The predicted product size for HOXA1 is 35 kDa and for actin 
42 kDa. The signals were quantified using the Gel-Pro Analyzer 6.0 and the signals were 
normalized to the actin loading control. 
 
2.2.3. Cell culture methods 
2.2.3.1. Cell culture conditions 
 
For thawing the cells a vial of frozen cells was transferred in a 37°C pre-warmed water bath 
and immediately mixed with ECGM. To remove DMSO from the cells a centrifugation step 
was performed and the supernatant was discarded and replaced against fresh ECGM. The 
resuspended cells were then plated in a T75 flask or 10 cm petri dish. 
To culture human umbilical vein endothelial cells (HUVEC) endothelial cell growth medium 
(ECGM) supplemented with 10% heat-inactivated foetal calf serum (FCS), 1% 
penicillin/streptomycin (P/S) and the corresponding supplements was used. For the assays 
HUVEC between passage 2 and 7 were used.  
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293A cells for the production of the adenovirus and the following experiments with 
adenovirus were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 
10% FCS and 1% P/S. 
To gain good stimulations in some angiogenic assay the HUVECs were starved over night 
before the assay was set up. Therefore the cells were cultured in basal medium without 
supplements, but with 2.5% FCS and 1%P/S. 
All cells were cultured in a humidified incubator at 37°C and 5% CO2. The cells were split 
1:3 using trypsin to passage the cells. For the HUVE cells T75 flask and for the 293A cells 
petri dishes (10cm, round) were used. 
 
2.2.3.2. Transfection of endothelial cells with siRNA 
 
In each case 120.000 HUVECs were seeded on a 6-well and incubated 24 h. On the second 
day they cells were transfected using oligofectamin. 10 µl (correspond 200 pmol) siRNA and 
90 µl OPTI-MEM were mixed and incubated for 10 min at RT. Additionally 6 µl 
oligofectamin mixed with 94 µl OPTI-MEM were incubated for 10 min at RT. After that time 
the siRNA and the oligofectamin mix were mixed and incubated for another 30 min at RT. 
Then the probes were adjusted to 1 ml OPTI-MEM. The HUVECs were washed twice with 
OPTI-MEM. Then the cells were transfected with the siRNA/oligofectamin-mix and 
incubated for 4 h in the humidified incubator. After this incubation the medium has to be 
changed to ECGM. After 24 h or 48 h the transfected cells were used for cellular or 
angiogenesis assays. 
 
2.2.3.3. Transfection of endothelial cells with adenovirus 
 
In each case 300.000 HUVECs were seeded on a 6-well and incubated 24 h. On the 
subsequent day cells were transfected with the HoxA1-adenovirus using a multiplicity of 
infection (MOI). For this transfection medium was extracted from the cells leaving 1 ml per 
well. 30 µl to 500 µl of virus lysate was added to the cells for a MOI of 35. After incubation 
time of 24 h in the humidified incubator the cells were washed twice with PBS and 2 ml 
ECGM was applied. Cellular and angiogenesis assay were performed either immediately or 
after additionally 24 h. 
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2.2.4. Cellular and angiogenesis assays 
2.2.4.1. Apoptosis assay 
 
This assay was performed with the Promega Caspase-Glo® 3/7 Assay System to investigate 
cell apoptosis via measurement of the Caspase 3 and 7 activities. For this HUVECs were 
transfected with HOXA1_A and HOXA1_B siRNA according to 2.2.3.2. or transduced with 
HOXA1-adenovirus according to 2.2.3.3. and 24 h after this transfection the cells were seeded 
in 96-wells with 10.000 cells per well in 100 µl ECGM. After additional 24 h the positive 
control cells were stimulated with 250 nM staurosporin for 2 h at 37°C in the humidified 
incubator. Then the medium was removed and the cells were lysed with 100 µl per well Glo-
Substrate solution for 1 h at RT. Finally the luminescence was measured with an ELISA 
reader. The assay was performed with triplicates for each condition and was performed 
minimum three times. The values were normalized to the control (con-siRNA or cherry-
adenovirus) transfected/transduced cells and not stimulated with staurosporin. 
 
2.2.4.2. Chemical hypoxia treatment 
 
150.000 HUVECs were seeded in a 6-well and treated with Dfx in a final concentration of 75 
µM or CoCl2 in a final concentration of 125 µM for 8 or 24 h. After 24 h hypoxia the cells 
were washed with PBS and new ECGM was added without Dfx or CoCl2 for additional 8, 24 
and 48 h to recover. To analyse the experiment, western blot lysates were made at the 
different time points focusing on HOXA1 expression levels. Untreated cells function as 
controls and were lysed at the beginning, at the middle and at the end of the experiment. 
 
2.2.4.3. Migration assay 
 
The migration assay was performed as a modified Boyden chamber assay. At the beginning 
the cells were transfected with the HOXA1_A or HOXA1_B siRNA and were 48 h after 
transfection starved overnight in starving medium. Also the nucleopore Track-Etch membrane 
was coated in 20 ml PBS + 100 µl 1 M NaOH + 200 µl chemotaxis collagen and was tried 
overnight. On the next day, the starving medium was incubated 30 min at 37°C in the 
humidifier incubator to avoid gas cavities. In the wells of the lower part of the Boyden 
chamber the medium was filled in, basal without and for stimulation with 25 ng/ml VEGF. 
The wells have to be filled until a meniscus is formed above the well. The membrane was 
placed with the brilliant side down onto the lower part of the chamber. Then the silicon layer 
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and the upper part of the chamber were placed above. HUVECs were adjusted to 450.000 
cells per ml and 52 µl of this cell suspension was given in triplicates to the wells on the upper 
part of the Boyden chamber. That the cells could migrate through the membrane the chamber 
was incubated for 3 h at 37°C in the humidifier incubator. To stain the migrated cells the 
membrane was first carefully removed from the chamber and fixed with the brilliant side up 
in 100 % ethanol for 10 min at RT. Afterwards the membrane was washed twice in MilliQ-
water and stained for 1 h at RT in staining solution. The staining solution exists of 9.9 ml 
Soerensen A + 15.1 ml Soerensen B + 1.25 ml Giemsa. Finally the membrane was washed 
twice and then placed with the brilliant side down on an object slide. To remove the non-
migrated cells the matt side of the membrane was cleaned with a cotton bud. The migrated 
cells were counted under the microscope, therefore 5 power fields per well were counted and 
the average was calculated. Average and standard deviation from the triplicates were 
calculated. The assay was performed four times and mean-values were calculated. 
 
2.2.4.4. Stimulation with growth factors 
 
This experiment was performed to investigate the effect of growth factors like VEGF or FGF 
on the HoxA1 expression level. 200.000 cells were seeded in a 6-well and incubated for 24 h 
by 37°C in the humidifier incubator. Then the cells were starved in starving medium 
overnight. At the next day the cells were stimulated with 25 ng/ml VEGF or FGF. After a 
stimulation time of 12 h respectively 24 h the cells were lysated and a Western Blot was 
performed. 
 
2.2.4.5. Sprouting assay 
 
For this assay HUVECs were transfected with HOXA1_A and HOXA1_B siRNA according 
to 2.2.3.2. or transduced with HOXA1-adenovirus according to 2.2.3.3. The sprouting assay 
was started 48 h after the transfection/transduction and was performed as described by Korff 
and Augustin (1998). Firstly the HUVECs were trypsinized and counted. 160.000 cells were 
resuspended in 10 ml ECGM containing 20% methocel. The cells were seeded in non-
adherent plastic plates with approximately 400 cells per 25 µl drop. The plates were turned to 
allow the cells to form spheroids in hanging drops. The hanging drops were incubated in a 
humidifier incubator for 24 h at 37°C. 
Material and Methods   
40 
 
On the next day the spheroids were harvested by washing with PBS and centrifugation at 
1000 rpm for 5 min and then the supernatant was aspirated. The spheroid-pellet was 
resuspended with 3 ml methocel containing 20% FCS. This solution was mixed with a 
collagen solution (3 ml Collagen + 375 µl Medium 199, pH 7.4 adjusted with 0.2% NaOH) 
and rapidly transferred into a 24-well suspension plate (1 ml per well). The gels have to 
polymerize for 30 min at 37°C in the humidifier incubator and then two wells per condition 
were stimulated with 25 ng/mL VEGF on top of the gel. Finally the assay was incubated for 
24 h in the humidifier incubator. The spheroids were fixed with 1 ml 10% PFA per well. 
In vitro angiogenesis was digitally quantified by measuring the length of the sprouts that had 
grown out of each spheroid (cumulative sprouting length). The sprouting length was measured 
using the Olympus IX50 microscope and the cell-P software analyzing at least 10 spheroids 
per experimental group and experiment. The experiment was performed in duplicates at least 
three times and mean-values were calculated. 
2.2.4.6. Tube formation assay 
 
At the beginning the cells were transfected with the HOXA1_A or HOXA1_B siRNA or 
transduced with HOXA1-adenovirus as described above. The assay was performed 48 h after 
the transfection or transduction of the cells. 
For this tube formation assay Matrigel has to thawed on ice and 150 µl chilled Matrigel was 
filled per 48-well. To get a solid matrigel the plate was incubated in a humidifier incubator for 
30 min at 37°C. Then 25.000 HUVECs in 250 µl ECGM were seeded on the solid matrigel 
per well. The medium contained 100 ng/ml VEGF which results in a final concentration of 25 
ng/ml. To form a network the assay was incubated for 24 h at 37°C in the humidifier 
incubator. After this time the formation of the network was stopped fixing with 240 µl 4% 
PFA. The cumulative sprouting length and the branching points were evaluated by using the 
Olympus IX50 microscope and the cell-P software. The assay was performed twice and 
mean-values were calculated. 
 
2.2.4.7. Viability assay 
 
To investigate if the transfection with HOXA1 siRNAs or the transduction with HOXA1-
adenovirus has an effect on the viability of the cells this assay was used for.  
For the investigation of the effects of the siRNA, HUVECs were transfected with HOXA1_A 
and HOXA1_B siRNA according to 2.2.3.2. To have enough cells two wells per condition 
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were transfected. 48 h after transfection the cells were seeded in 24-wells with 30.000 cells 
per well. 24, 48 and 72 h after seeding the cells were trypsinized and counted. The assay was 
performed in triplicates, the mean-values were calculated and a growth curve was designed. 
For the investigation of the effects of the adenovirus, HUVECs were transduced with 
HOXA1-adenovirus according to 2.2.3.3. but only 120.000 cells were seeded per 6-well. One 
day later, 24 h after the transduction, the cells were trypsinized and counted. The other cells 
were washed with PBS and new ECGM was added and were incubated for additional 24 h or 
48 h. So 48 h and 72 h after transduction the cells were trypsinized and counted. The assay 
was also performed in triplicates, the mean-values were calculated and a growth curve was 
designed. 
 
2.2.5. Animal experiments 
2.2.5.1. Zebrafish 
2.2.5.1.1. Zebrafish maintenance 
 
The Zebrafish lines were raised and staged as described (Kimmel et al. 1995) under standard 
husbandry conditions (Lawson and Weinstein, 2002) in the Center for Biomedicine and 
Medical Technology, Mannheim, Division for Vascular Biology and Tumorangiogenesis. 
Embryos were kept in E3 solution at 28.5°C with or without 0.003% 1-phenyl-2-thiourea 
(PTU) to suppress pigmentation and staged according to somite number or hours post-
fertilization (hpf). 
2.2.5.1.2. Morpholino injection 
 
The morpholino was solved in MilliQ water in a stock solution of 16 µg/µl. The morpholino 
was diluted in 0.1 M KCl to concentrations of 2 to 8 µg/µl. The dilution was incubated for 5 
min at 65°C. 1 nl of the respective dilution was injected through the chorion into the yolk sac 
of 1-cell stage embryos. 
2.2.5.2. Mouse 
2.2.5.2.1. Mouse maintenance 
 
The care and experimental use of the mice were in accordance with institutional guidelines 
and in compliance with the Association for Research in Vision and Ophthalmology (ARVO) 
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statement. Female C57BL/6 mice were purchased and housed in a 12 h light/dark cycle with 
free access to food and drinking water. 
2.2.5.2.2. Oxygen-induced retinopathy (OIR) mouse model 
 
The oxygen-induced retinopathy (OIR) mouse model was performed as described in Kroll et 
al. (2009). At postnatal day 7, newborn mice were exposed to 75% oxygen for 5 days with 
their nursing mothers, and subsequently returned to room air. All animals were weighted and 
randomly divided into groups (DMSO, H-1152, Fasudil and Y27632) and once per day 
injected intraperitoneally for five consecutive days from postnatal day 12 to 16. At postnatal 
day 17, the animals were sacrificed, and one eye per mouse was fixed in 4% formalin and the 
second eye was frozen in N2 at -80°C. From the eye fixed in formalin serial paraffin sections 
(6 µm) were stained with periodic acid-Schiff and hematoxylin. The numbers of nuclei in 
preretinal neovascularizations were counted.  
 
2.2.5.3. Rat 
2.2.5.3.1. Rat maintenance 
 
Ten week old male Wistar rats (n = 40) were staged under standard conditions in groups, 4 
per cage, at the animal facility of the University of Groningen and had free access to food and 
drinking water throughout the study. All animal experiments were accomplished in approval 
with the US National Institutes of Health Guide for the Care and Use of Laboratory Animals 
and approved by the Committee for Animal Experiments of the University of Groningen, 
Netherlands. 
 
2.2.5.3.2. Myocardial infarction rat model 
 
The myocardial infarction study was performed as described in Lutgens et al. (1999), by 
permanent ligation of the left coronary artery. Rats were anesthetized and the thorax was 
opened in the fourth intercostals space and the muscles overlying this region were dissected. 
The main left anterior coronary artery was ligated. Directly after the induced myocardial 
infarction the rats get an osmotic minipump in the neck. The rats were divided into three 
groups: (i) sham group (control I; n = 8), (ii) control group II (water; n = 16) and (iii) 
treatment group (H1152 (3 mg/kg/day); n = 16). 
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2.2.6. Microarray analysis 
 
The microarray analysis was performed using HUVECs transfected with control- or 
HOXA1_A or HOXA1_B siRNAs. RNA was isolated from the cells 48 hours after the 
transfection. The RNA samples were sent to the Core Facility “Genom and Proteom” of the 
DKFZ, which performed the microarray analysis and sent afterwards the results. This analysis 
was carried out in biological quadruples. 
2.2.7. Flow cytometry 
 
This technique was used to analyze the expression of HOXa1a in GFP positive cells. 
Therefore tg(fli1:EGFP) embryos were injected as described in 2.2.5.1.2. At 48 hpf the 
embryos were anesthetized and dechorinated. Then the embryos were incubated in modified 
Ringer solution and deyolked by pipeting up and down with a 200 µl pipet. Before the lysis 
the embryos were washed in PBS and then lysed in 0.25% trypsin for 20 min. The reaction 
was stopped with PBS containing 10% FCS and 2 mM CaCl2. Finally the cells were 
centrifuged and resuspended in FACS buffer. Using a FACScan flow cytometer with 
CellQuest software (Becton Dickinson) GFP positive cells were sorted. These positive cells 
were then used for PCR analysis. 
2.2.8. Imaging 
2.2.8.1. Immunocytochemical staining 
 
Before the cell staining a transfection with siRNAs as described in 2.2.3.2 was performed. 48 
h after the transfection the cells were seeded in a 24-well adhesion plate. Cover slips were 
coated with fibronectin in PBS (1:200) for 30 min at 37°C in the humidifier incubator. Then 
the fibronectin was removed from the slips and 50.000 cells were seeded per well onto the 
cover slips and incubated over night in the humidifier incubator. On the next day the cells 
were washed twice with PBS and then fixed with 4% PFA for 30 min at RT. The cells were 
subsequently permeabilized in 0.3% TritonX-100 in PBS for 10 min followed by a washing 
step with PBS. Then the blocking solution, 3% BSA in PBS, was applied for 30 min. The 
primary antibody was diluted in blocking solution and was used in a final concentration of 5 
µg/ml. The cells were incubated with the primary antibody for 1 h at RT. Then the cells were 
washed three times in PBS and then the secondary antibody was applied for 30 min. The 
secondary antibody was diluted in PBS and used in a final concentration of 8 µg/ml. To 
visualize the nuclei the cells were counterstained with DAPI (final concentration: 2 µg/ml) for 
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10 min and then the cover slips were removed from the 24-well plate and embedded with 
Fluoromount Medium on an object slide. 
 
2.2.8.2. Immunohistochemical staining 
 
To stain retinas with Isolectin B4, the eyes were incubated with 4% PFA over night at 4°C 
and were then washed three times for 10 min with PBS. Then the retinas were dissected from 
the eyes and were then blocked in steril filtered 1% BSA in PBS with 0.5% Triton-X-100. 
The retinas were blocked over night at 4°C. On the third day the retinas were washed five 
times for 10 min with PBS. Then the retinas were incubated with pBLEC (0.1 mmol CaCl2, 
0.1 mmol MgCl2, 0.1 mmol MnCl2, 1% Triton-X-100 in PBS; pH = 6.8) two times for 1 hour. 
The retinas were stained with Isolectin B4 at 4°C over night in a concentration of 1:100. 
Finally on the fourth day, the retinas were washed 5 times for 1 h with PBS followed by the 
embedding with Fluoromount Medium on an object slide. The branching points were counted 
physically without a software program. 
 
2.2.8.3. Whole mount staining of zebrafish 
 
To enhance the GFP-signal a whole mount antibody staining against GFP was performed. All 
steps were performed on a rotating platform. Tg(fli1:EGFP) embryos were fixed in 4 % PFA 
for 2 h at RT or overnight at 4°C. Then the embryos were washed 3 times 5 min in PBST, 
were dehydrated in methanol (25%, 50% and 75% methanol, 5 min each) and stored at -20°C 
(minimum 2 h). To stain the embryos were first rehydrated (75%, 50% and 25% methanol, 10 
min each) and washed 4 times 5 min in PBST. Then the embryos were permeabilize using 10 
µg/ml Proteinase K in PBST. 48 hpf embryos were treated 20 min whereas 72 hpf embryos 
were treated 1 h. After washing 2 times 5 min in PBST they were fixed again with 4% PFA 
for 15 min at RT. Then the embryos were washed again 4 x 5 min in PBST and equilibrated in 
PBSTT for 5 min. The embryos were then blocked in 1% BSA in PBSTT containing 2% 
sheep serum. The anti-GFP antibody was diluted in blocking solution in a final concentration 
of 10 µg/ml and was applied at 4°C over night. On the following day the embryos were 
washed 2 times 5 min in PBSTT and then minimum 6 times for 1 h. The secondary antibody 
was taken from the ABC Vectastain kit and added to the following solution: 2 ml PBST + 30 
µl blocking serum from rabbit + 10 µl secondary antibody. The embryos were also incubated 
with the secondary antibody at 4°C over night. On the next day the embryos were washed 
again 2 x 1min and 1 x 30 min with PBSTT. The ABComplex from the Vectastain kit was 
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incubated 30 min during this time and then applied to the embryos for an incubation time of 1 
h. Before quenching the embryos were washed 2 x 1 min and 3 x 20 min with PBSTT, then 
the endogenous peroxidise was quenched using 1% H2O2 in PBSTT for 15 min and 
subsequently washed 3 x 5min in PBSTT. Then an equilibration step followed for 15 min in 
100 mM TrisHCl buffer/Tween20 and afterwards the embryos were preincubated with 
DAB/TrisHCl staining solution for 10 min. Then 0.012% H2O2 was added and the embryos 
were incubated in the dark for approximately 10 min until the desired staining intensity was 
reached. The reaction was stopped by washing 4 x 10 min with PBST and then the embryos 
were post-fixed in 4% PFA over night at 4°C. Finally the stained embryos were washed with 
PBST 3 times for 5 min and analyzed under the microscope. The embryos were stored in 
100% glycerol at 4°C. 
2.2.8.4. Microscopy 
 
Angiogenesis in vitro assays (described in 2.2.4.5. and 2.2.4.6.) were analyzed using the 
Olympus IX50 microscope and the cell-P software. 
The in vivo images from the trunk with the tg(fli1:EGFP) embryos were made using the 
confocal microscope DMIRE2 with Leica TCS SP2 True Confocal Scanner (Leica 
Microsystems). Confocal images of the zebrafish head vasculature were made with the Nikon 
C1-CLEM confocal laser scanning system and the Nikon A1R confocal laser scanning 
microscope. Therefore the embryos were dechorinated, anesthetized with 0.003% tricaine and 
embedded in 1% low-temperature melting agarose.  
Overview pictures of embryos, and mouse tissues as well as HUVEC were analyzed with the 
fluorescence microscope DMI 6000 B (Leica), the fluorescence microscope Axio Imager 2 
(Zeiss) and the inverted light microscope Type 090-135.001 (Leica). 
2.2.9. Statistical and phylogenetic analysis 
 
All results are expressed as mean ± standard error of the mean (SEM). To define significant 
differences of experimental groups, the two-tailed student t-test was used. p<0.05 was 
considered as statistically significant. For protein alignment analysis and phylogenetic 
relationship the sequences of HoxA1 proteins from invertebrates and vertebrates the 
bioinformatic program ClustalW was used (Thompson et al., 2002). To analyse the results of 
the microarray the CSC Chipster software package and the Ingenuity Pathway Analysis 
software were used. 
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3. Results – HOXA1 
 
3.1. Expression of HOXA1 
 
 
During a number of angiogenic processes, for example sprouting and migration, normal 
angiogenesis as well as pathological angiogenesis, several members of the HOX transcription 
factor family play a crucial role (Cantile et al. 2008). HOXA1 was reported to be expressed in 
anterior regions mainly in the pharyngeal arch and brain regions, predominantly hindbrain and 
tegmentum, during zebrafish development (Thisse et al., 2005). From mouse embryonic day 
7.75 to 8.5, HOXA1 is highly expressed in the neuroectoderm and mesoderm during 
hindbrain development (Murphy and Hill, 1991). Moreover HOXA1 expression was also 
detected in a diversity of human breast cancer lesions, suggesting that HOXA1 may be 
required for the establishment of breast cancer cells (Chariot and Castronovo, 1996). If 
HOXA1 is expressed in endothelial cells and the role of HOXA1 during angiogenesis was 
unknown until now.  
 
3.1.1. HOXA1 is an evolutionary conserved protein  
 
HOXA1 is ubiquitously expressed among species and is highly conserved. Figure 11A shows 
the evolutionary relationship between the HOXA1 proteins found in vertebrates. HOXA1 
consists of a homeobox domain. This homeobox domain is 183 bp long, 61 amino acids 
respectively and encodes a protein domain, which can bind DNA. The identity between the 
amino acids sequences of human and mouse HOXA1 is 93%. Between human and zebrafish 
the identity of the amino acids sequence is 56% and also 56% between mouse and zebrafish 
(Figure 11B). The homeodomain of all three species exhibits 100% identity in the amino acids 
sequence. The human HOXA1 linear DNA have 10014 bp, the linear mRNA consists of 2517 
bp, the complete coding region (cds) consists of 1008 bp and the protein consists of 335 
amino acids, which results in 36 kDa. The zebrafish HOXa1a gene consists of 990 bp and the 
protein of 36 kDa (329 amino acids). 
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Figure 11: HOXA1 is highly conserved during vertebrate development. (A) Phylogenetic analysis of 
HOXA1 proteins from different vertebrates. This analysis shows that HOXA1 is highly conserved throughout 
evolution. The numbers indicates the relative evolutionary distance. (B) Multiple amino acid comparison of 
human (Homo sapiens), mouse (Mus musculus) and zebrafish (Danio rerio) sequences of HOXA1. The numbers 
indicates the amino acid positions. Conserved amino acids are labelled with an asterisk. The red line represents 
the homeobox domain. Accession codes: Homo sapiens (NP_005513.1), Mus musculus (NP_034579.3), Danio 
rerio (Q98SI1.1), Rattus norvegicus (NP_037207.1), Cavia procellus (XM_003467943.1). 
 
 
Results   
48 
 
3.1.2. HOXa1a is expressed in zebrafish 
 
To analyse HOXa1a expression in zebrafish, mRNA was isolated or lysates for Western Blot 
analysis were extracted. RNA was isolated 24, 48, 72 and 120 hours post fertilization and RT-
PCR was performed. figure 12a shows that HOXa1a is highly expressed during zebrafish 
development. Also on protein level (Figure 12b) HOXa1a is expressed from 24 hpf until 96 
hpf.  
 
Figure 12: HOXa1a is expressed in zebrafish. (A) PCR shows HOXa1a expression 24 hpf, 48 hpf, 72 hpf and 
120 hpf. (B) Western Blot analysis shows HOXa1a expression 24 hpf, 48 hpf, 72 hpf and 96 hpf as well.  
 
Endothelium specific HOXa1a expression was analysed with FACS and RT-PCR. Wildtype 
and tg(fli1:EGFP) zebrafish embryos were trypsinized 48 hours post fertilization and the cells 
were sorted for GFP-positive cells explicitly endothelial cells. This shows that HOXa1a is 
expressed in zebrafish endothelial cells (Figure 13). 
 
Figure 13: HOXa1a is expressed in endothelial cells in tg(fli1:EGFP) zebrafish. (A) Control from wildtype 
zebrafish embryos. All cells are GFP negative. (B) tg(fli1:EGFP) zebrafish embryos show GFP positive cells 
with 99.1% purity during FACS. (C) PCR with GFP positive cells showing HOXa1a expression. 
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3.1.3. HOXA1 is expressed in human umbilical vein endothelial cells and 
bovine aortic endothelial cells 
 
Human umbilical vein endothelial cells (HUVEC) and bovine aortic endothelial cells (BAEC) 
were stained for HOXA1 to study its expression in the cells. The cells were additionally 
stained with DAPI to investigate the localization of HOXA1 in the nucleus. In agreement to 
HOXA1 function as a transcription factor the protein is localised in the nucleus (Figure 14). 
 
Figure 14: HOXA1 is expressed in HUVECs and BAECs. HOXA1 is localized in the nucleus. Cells were 
stained with an Anti-HOXA1 antibody and DAPI. Scale bar: 20 µm. 
 
 
3.2. Zebrafish show vascular defects after HOXa1a silencing 
 
 
Experiments were performed to focus on the in vivo relevance of HOXa1a using zebrafish 
studies. In order to silence HOXa1a in zebrafish a translational blocking morpholino (TB-Mo) 
was used. These translational blocking morpholinos block the “translation initiation in the 
cytosol by targeting the 5' UTR through the first 25 bases of coding sequence” (www.gene-
tools.com). First a Western Blot analysis was performed to prove the functionality of the 
HOXa1a morpholino. Therefore zebrafish embryos were injected in the 1-cell stage with 2 ng 
and 4 ng of the HOXa1a-TB-Mo and after 24 h, 48 h, 72 h and 96 h the embryos were lysed. 
The Western Blot shows that the morpholino works until 96 hpf (Figure 15) because the 
intensity of HOXa1a expression is lower in the lysates from HOXa1a-TB-Mo injected 
zebrafish. 
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Figure 15: Western Blot analysis shows that the HOXa1a-TB-Mo downregulates HOXa1a level after 24 
hpf until 96 hpf. The figure shows one Western Blot per time point.  
 
3.2.1. Zebrafish show vascular defects in the trunk vasculature after 
HOXa1a silencing 
 
HOXa1a silencing via morpholino injection led to an impaired blood vessel formation. Some 
intersomitic vessels (ISV) are not completely developed and some ISVs do not even begin to 
sprout from the dorsal aorta. The formation of the dorsal longitudinal anastomotic vessel 
(DLAV) is also affected. Mostly the impaired DLAV formation is a subsequent result of the 
impaired ISV formation. The morphology of the zebrafish looks normal so side effects of the 
injection can be excluded (Figure 16). 
 
 
Figure 16: Specific phenotype in the zebrafish trunk vasculature after HOXa1a silencing with morpholino 
injection in a concentration of 2 ng respectively 4 ng. A, A’: The con-Mo injected embryo showed a normal 
morphology (A) and a normal vascular system (A’). The black box marks the area which is shown in A’. B, B’: 
The HOXa1a-Mo injected embryos with an injection volume of 2 ng showed a normal morphology (B) but 
defects in the vasculature (B’). Impaired ISV formations are indicated by arrows and breaks in the DLAV are 
marked with arrowheads. The black box marks the area which is shown in B’. C, C’: The HOXa1a-Mo injected 
embryos with an injection volume of 4 ng showed a normal morphology (C) but defects in the vasculature (C’). 
Impaired ISV formations are indicated by arrows and breaks in the DLAV are marked with arrowheads. The 
black box marks the area which is shown in C’. Black scale bar: 500 µm. White scale bar: 50 µm. 
 
  Results 
51 
 
To quantify this phenotype a DAB staining, to enhance the GFP signal, was performed, in 
which 40 zebrafish in each group were analysed. After 48 h 62% of the embryos injected with 
2 ng of HOXa1a morpholino showed defects in the ISVs and 67.5% of the embryos with 4 ng 
injection volumes. After 72 h the results were nearly the same, 70% (2 ng) and respectively 
67.5% (4 ng) of fish were affected (Figure 17). 
 
Figure 17: Quantification of the phenotype of impaired ISV formation. A number of 40 embryos were 
analysed and more than a half of the morpholino injected fish showed impaired vessel formation. 
 
Figure 18: Quantification of the phenotype of impaired DLAV formation. A number of 40 embryos were 
analysed and after 48 hpf the half of the morpholino injected fish showed impaired vessel formation. After 72 
hpf only a few injected fish showed defects in the DLAV.  
3.2.2. Zebrafish show vascular defects and cranial haemorrhages in the 
head vasculature after HOXa1a silencing 
The expression level of HOXa1a in anterior regions is higher than in the rest of the organism 
(see 3.1. and introduction), suggesting a phenotype in the head of the zebrafish. After 
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HOXa1a silencing cranial haemorrhages arise in zebrafish (Figure 19). Nevertheless the 
embryos survive until the observation time of 120 hpf and their morphology looks normal 
(see also 3.2.1. and Figure 16). The head bleeding starts at approximately 24 hpf and this 
phenotype is not reversible. The fish with bleedings after 24 hpf were separated and at 48 hpf 
all bleedings were still there. The fish were observed until 120 hpf and until this point in time, 
the head bleeding does not regress. Table 1 shows the quantification of the cranial 
haemorrhages. After 48 hpf around 20% of the fish observed were affected by head bleeding. 
After 72 hpf around 30% of the fish suffer from head bleeding. As described before, all fish 
displaying head bleeding after 48 hpf also had head bleeding after 72 hpf. 
 
 
Figure 19: Cranial haemorrhages in zebrafish after HOXa1a silencing. (A) Zebrafish at 48 hpf injected with 
con-Mo. (A’) Zebrafish at 72 hpf injected with con-Mo. (B) Zebrafish at 48 hpf with an injected volume of 2 ng 
HOXa1a-Mo. (B’) Zebrafish at 72 hpf with an injected volume of 2 ng HOXa1a-Mo. (C) Zebrafish at 48 hpf 
with an injected volume of 4 ng HOXa1a-Mo. (C’) Zebrafish at 72 hpf with an injected volume of 4 ng 
HOXa1a-Mo. Arrows mark the positions of cranial haemorrhages. Black scale bar: 500 µm. 
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Table 1: Quantification of zebrafish after HOXa1a silencing shows that a loss of function of HOXa1a leads 
to cranial haemorrhages. Zebrafish were observed after 48 hpf and 72 hpf. Zebrafish injected with control 
morpholino show a lower number of zebrafish with bleedings than zebrafish injected with HOXa1a-Mo. At 72 
hpf more zebrafish are affected from cranial haemorrhages. At 48 hpf the zebrafish with bleeding were separated 
and all these fish show cranial haemorrhages at 72 hpf. 
 
48 hpf         
    
  con-Mo 2 ng con-Mo 4 ng HOXa1a-Mo 2 ng HOXa1a-Mo 4 ng 
total 131 138 112 165 
 - bleeding 129 129 88 148 
+ bleeding 2 9 24 17 
      
% bleeding 1,53 6,52 21,43 10,30 
    
    
72 hpf   
    
  con-Mo 2 ng con-Mo 4 ng HOXa1a-Mo 2 ng HOXa1a-Mo 4 ng 
total 130 138 104 159 
 - bleeding 115 115 72 113 
+ bleeding 15 23 32 46 
      
% bleeding 11,54 16,67 30,77 28,93 
 
To further investigate the influence of HOXa1a silencing in the zebrafish, confocal images of 
the head were made to investigate vessel formation. The vessels in the head vasculature are 
also severely affected after HOXa1a silencing. Especially in the hindbrain vasculature, the 
central arteries are absent or malformed (Figure 20). The central arteries are sub-divided into 
three groups: Cerebellar central artery (CCtA), middle mesencephalic central artery (MMCtA) 
and posterior (caudal) mesencephalic central artery (PMCtA) (Isogai et al., 2001). All three 
types of central arteries are affected after HOXa1a silencing. Besides absent or malformed 
central arteries, small fine sprouts can also be observed. These sprouts grow unregulated in 
every direction, but this phenomenon is only seen at 48 hpf. 
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Figure 20: Confocal images of the head vasculature of zebrafish at 48 hpf (A, B, C) and at 72 hpf (A’’, B’’, 
C’’) show defects in the central arteries. The red boxes mark the areas shown in A’, B’ and C’. White 
arrows indicate the absent or malformed CCtA, red arrows indicate the absent or malformed PMCtA and the 
arrowheads the malformed MMCtA. The asterisks show the regions of abnormal sprouting. 
3.3. HOXA1 is a positive regulator of angiogenic processes in vitro 
 
To confirm the phenotype from the zebrafish experiments in vitro experiments were 
performed which is described in the following sections. For the following in vitro experiments 
the siRNAs HOXA1_A and HOXA1_B were used and a control-siRNA (consi) was used. 
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Therefore HUVEC-staining and Western Blot analysis after siRNA transfection were 
performed to investigate the quantity of HOXA1 downregulation. The qualitative analysis 
with HUVEC-staining show a downregulation of HOXA1 after siRNA transfection (Figure 
21A) as does the quantitative Western Blot analysis (Figure 21B). The siHOXA1_A leads to a 
downregulation of 62% and siHOXA1_B of 68%.  
 
 
 
Figure 21: HOXA1 is downregulated after siHOXA1 transfection. (A) HUVECs were stained with Anti-
HOXA1 antibody and DAPI after transfection with consiRNA, siHOXA1_A and siHOXA1_B. Merge pictures 
show the localization of HOXA1 in the nucleus. Scale bar: 20 µm (B) Western Blots show the downregulation of 
HOXA1 after siRNA transfection. The bar graph shows the quantification as an average of three independent 
experiments.  
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3.3.1. Downregulation of HOXA1 inhibits migration of HUVEC in a VEGF 
independent manner 
 
One of the major processes in angiogenesis is cell migration. Migration of HUVEC was 
analysed by the modified Boyden chamber assay. Quantification was calculated by migrated 
cells per power field to test the effect of HOXA1 on this angiogenic process. Therefore, 
siHOXA1_A and siHOXA1_B transfected cells were examined and compared to consiRNA 
control cells (Figure 22). Downregulation of HOXA1 in HUVEC showed a significantly 
reduced migration. This result suggests that HOXA1 is a proangiogenic regulator. But 
HOXA1 does not regulate VEGF dependent angiogenesis because this reduced migration was 
seen in VEGF stimulated cells as well as in unstimulated cells. 
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Figure 22: HOXA1 promotes migration in HUVECs. siRNA mediated Hoxa1 downregulation significantly 
inhibited basal and VEGF-driven endothelial cell migration in the modified Boyden chamber assay. Mean values 
of four independent experiments. * P < 0.05 compared with control basal. 
 
3.3.2. Downregulation of HOXA1 inhibits sprouting of HUVEC  
 
Another important process during angiogenesis is sprouting. To study the impact of HOXA1 
on sprouting, a sprouting assay was performed. The siHOXA1_A and siHOXA1_B 
transfected cells were examined and compared to consiRNA control cells (Figure 23). 
Downregulation of HOXA1 in HUVEC showed a significantly reduced sprouting. This 
enforces the conclusion in 3.3.1 that HOXA1 is a proangiogenic regulator. In the sprouting 
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assay, it was also shown that HOXA1 does not regulate VEGF dependent angiogenesis 
because this reduced sprouting was seen in VEGF stimulated cells as well as in unstimulated 
cells. 
 
Figure 23: HOXA1 is an important factor during sprouting processes. (A) siRNA mediated HOXA1 down-
regulation strongly decreases endothelial sprouting. (B) Quantification of the experiment shown in (A). Mean 
values of six independent experiments. * P < 0.05 compared with control basal. 
 
 
3.3.3. Downregulation of HOXA1 does not lead to apoptosis and does not 
inhibit viability of HUVEC 
 
The viability of HUVEC was analysed to exclude unspecific effects of the siRNA 
transfection, which can influence the results of the migration and sprouting assays. The assay 
was performed as described in 2.2.4.7 and a growth curve was developed (Figure 24). 
HUVEC were counted at the beginning of the experiment and after 24 h, 48 h and 72 h. The 
growth curves show that all samples, the control siRNA and both HOXA1 siRNAs revealed 
continuous growth and no symptom of cell death during the experiment. The treatment of 
cells with siRNA does not influence the growth curves of the cells, excluding cytotoxic side 
effects of the siRNA. 
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Figure 24: siRNA mediated HOXA1 down-regulation does not influence viability of HUVEC. The cell 
number was counted at the indicated time points after transfection with consi, siHOXA1_A and siHOXA1_B. 
Mean values of three independent experiments are shown. 
 
 
Secondly the effect of siRNA transfection on cell apoptosis was analysed. HUVECs were 
transfected with consiRNA, siHOXA1_A and siHOXA1_B and the caspase activity was 
measured as described in 2.2.4.1. As a control for apoptosis, HUVECs were treated with 250 
nM staurosporin to induce cell apoptosis. As figure 25 shows, transfection of siHOXA1_A or 
siHOXA1_B did not provoke cell apoptosis. 
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Figure 25: siRNA mediated HOXA1 downregulation does not induce cell death in HUVEC. Mean values of 
three independent experiments are shown. * P < 0.05 compared with consi. 
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3.3.4. Downregulation of HOXA1 shows less tube formation in HUVECs 
Aside from the basic cellular processes of sprouting and migration, it is also possible to study 
the mechanism of angiogenesis with the tube formation assay. HUVECs were transfected with 
HOXA1-siRNAs and seeded on a matrigel. The cells were stimulated with VEGF to reflect 
the in vivo situation. The cumulative sprouting length and the number of branching points 
were measured and are shown in figure 26. This figure also illustrates representative pictures 
of the network in each condition. 
 
 
Figure 26: HOXA1 knock-down with siRNA transfection leads to an incomplete network formation in 
HUVECs. (A) Number of branching points in the control and after HOXA1_A and HOXA1_B transfection. (B) 
Cumulative sprouting length was measured in the control and after HOXA1_A and HOXA1_B transfection.  (C) 
Representative pictures show the network formation in the afore mentioned conditions. Mean values of two 
independent experiments are shown. 
 
The branching points, as well as the cumulative sprouting length, are influenced by HOXA1-
siRNA transfection. Although the number of branching points and the cumulative sprouting 
length is lower, this effect is not significant. Furthermore, a statistic analysis is impossible as 
only two experiments were performed. Only two experiments were performed because no 
significant effect was observed. Nevertheless the tube formation assay gives an indication that 
HOXA1 is a pro-angiogenic factor. 
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3.3.5. HOXA1 is a regulator of angiogenic processes independently of the 
VEGF-pathway and is not influenced under hypoxic conditions 
To confirm the data resulting from the sprouting assay and the migration assay, a stimulation 
experiment with growth factors was performed. HUVECs were stimulated with either VEGF 
(25 ng/ml) or FGF (25 ng/ml) for 12 h (data not shown) respectively 24 h (Figure 27) 
followed by a Western Blot analysis with an HOXA1 antibody. The levels of HOXA1 did not 
change in comparison to the control, which was not stimulated (Figure 27). So it seems that 
HOXA1 is not influenced by VEGF signalling and concordantly to the angiogenesis assays, 
where it was shown that migration and sprouting are reduced in a VEGF-independent manner 
(see 3.3.1. and 3.3.2.). 
 
Figure 27: Western Blot after HUVEC stimulation with 25 ng/ml VEGF or 25 ng/ml FGF. (A) Actin 
functions as a loading control. There are no appreciable differences between the bands of the different 
conditions. One representative Western Blot is shown. (B) Statistical analysis show mean values of three 
independent experiments.  
 
To investigate hypoxic influence on HOXA1 expression HUVECs were chemically treated 
(Wang and Semenza, 1993). HOXA1 is not influenced under hypoxic conditions with Dfx or 
CoCl2. Western Blot analysis shows no alterations between the probes, neither during hypoxia 
nor at different time points after recovery (Dfx treatment: Figure 28; CoCl2 treatment: data 
not shown). 
 
 
Figure 28: HOXA1 is not influenced with Dfx treatment. HUVECs were treated for 8 or 24 h with Dfx and 
recovered for 8 or 24 h in normoxic conditions. Untreated cells served as controls (0 h, 48 h and 72 h). The 
Western blot shows no differences of the expression levels of HOXA1. 
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3.4. Identification of HOXA1 target genes 
 
Microarray analysis was performed to identify potential target genes of HOXA1. The 
microarray was executed 48 hours after siRNA transfection, thus at that point in time the in 
vitro angiogenesis assays were performed. The microarray was carried out using triplicates to 
assure validated results. Few genes were significantly up- or downregulated. The microarray 
was analysed using the CSC Chipster software package. A significant regulation was defined 
as 0.005 and with this threshold 26 genes were significantly regulated after HOXA1 
knockdown with siHOXA1_A (Figure 29A). In the case of knockdown with siHOXA1_B, 20 
genes were significantly regulated (Figure 29B). Among these genes the SELE gene, which 
encodes for E-selectin, was highly downregulated after HOXA1 silencing (Figure 29C).  
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Figure 29: Global gene expression analysis after downregulated HOXA1 expression. (A+B) Data 
representation of the microarray results by a heat map using the CSC Chipster software package. Upregulated 
genes are labelled in different shades of red and downregulated genes are labelled in shades of green. n = 3 
experiments were analysed. (C) Interesting genes of endothelial cell biology which are regulated by HOXA1. 
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Interestingly, the majority of the regulated genes are involved in cell-to-cell signalling and 
interaction (Figure 30). Also in an inflammatory response and in cancer, the regulated genes 
involved indicate the potential role of HOXA1 in these processes.  
 
Figure 30: The majority of regulated genes in the microarray are involved in cell-to-cell signalling. The 
regulated genes were attributed to their functions using the Ingenuity Pathway Analysis software. HOXA1 
regulated genes are mainly involve in cell-to-cell signalling and interaction.  
 
3.4.1. E-selectin as a potential target gene of HOXA1 
 
E-selectin is downregulated after HOXA1 downregulation in HUVECs (Figure 29C). The 
expression of E-selectin is more than 50% lower in comparison to the control. To confirm the 
data from the microarray analysis, a RT-PCR was performed. First HOXA1 was 
downregulated with siRNA transfection and after 48 h (according to the procedure used in the 
microarray) the cells were lysed. After RNA and cDNA production a PCR for E-selectin was 
done (Figure 31A). The quantitative analysis showed that E-selectin is expressed only 33% 
and 37% respectively of the expression level in the control (Figure 31B). HOXA1 siRNAs 
lead to lower cell densities and this could lead to a lower expression of the adhesion molecule 
E-selectin, an additional control was used. As an additional control a siRNA which 
downregulates the BTB-kelch-protein KLEIP was used because this siRNA is known to lead 
to a lower cell density. To exclude that E-selectin, which is an adhesion molecule, is 
downregulated due to missing cell junctions, the KLEIP siRNA was used. The KLEIP siRNA 
probe showed no difference in the expression level of E-selectin. 
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Figure 31: E-selectin is downregulated after HOXA1 downregulation. (A) Agarose-Gel after RT-PCR 
showed clearly that in the siHOXA1 transfected probes E-selectin is highly downregulated compared to the 
control. (B) Quantitative analysis of the experiment shown in A. E-selectin expression was only 33% 
respectively 37% compared to the E-selectin expression in the control. Mean values of three independent 
experiments are shown. * P < 0.05 compared to consi. 
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4. Results – Rho-dependent kinases ROCK I/II 
 
The small GTPase RhoA activates the serine/threonine kinases ROCK I and ROCK II (see 
1.5.). Inhibition of the Rho kinases with different inhibitors, leads to contrary findings in vivo 
and in vitro which are controversially discussed. In this study the Rho kinases where inhibited 
with H1152, Fasudil and Y27632 in the oxygen-induced retinopathy (OIR) mouse model 
(4.1.) and with H1152 in the myocardial infarction study (4.2.). 
 
4.1. Inhibition of Rho-dependent kinases with different inhibitors 
in the oxygen-induced retinopathy (OIR) mouse model 
 
The OIR model was used to investigate angiogenic processes in the retina. In the OIR mouse 
model the mice were exposed to 75% oxygen at postnatal day 7 till postnatal day 12. At 
postnatal day 12 the mice were returned to room air and treated with the inhibitors from the 
12 till day 16 (see also Material and Methods). In this study, all three Rho kinases inhibitors 
were used: the very specific inhibitor H1152, the inhibitor Fasudil and the inhibitor Y27632. 
The experiment was performed according to the procedures described in Kroll et al., 2009 
(2.2.5.3.2.) but more Rho kinase inhibitors were tested. 
 
4.1.1. Inhibition of ROCK I/II with H1152 and Fasudil shows higher neo-
vascularization 
The inhibition of Rho kinases I and II was shown to advance endothelial function in patients 
with coronary artery diseases (Nohria et al., 2006). The OIR model is appropriate to 
investigate the mechanisms of endothelial cell activation and angiogenesis (Feng et al., 2007). 
Mice injected with H1152 and Fasudil showed an increase of pre-retinal new vessels in 
comparison with the control mice injected with DMSO (Figure 32A). Injection with Y27632 
shows no variance in the amount of pre-retinal new vessels (Figure 32B). 
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Figure 32: Pharmacological inhibition of Rho kinases increase angiogenesis in mouse retinas. (A) Injection 
with Fasudil showed an increase of 50% and injection with H1152 an increase of 25%. Mean values of three 
independent experiments are shown. From each retina 10 sections were counted. (B) Injection with Y27632 
showed no effect. Mean values of three respectively four independent experiments are shown. From each retina 
10 sections were counted. (C) Representative pictures of retinas injected with DMSO (control), H1152 and 
Fasudil.  
4.1.2. Isolectin staining shows higher retinal vascularization after ROCK 
I//II inhibition 
 
An isolectin staining was performed to investigate at the growth and formation of endothelial 
cells in the retina after the OIR experiment (Figure 33). The retinas of mice injected with 
H1152 showed more vascularization. The network formed consists of more branching points 
in comparison to the control retinas of mice injected with DMSO (Figure 34). So more vessels 
developed, which indicates an anti-angiogenic effect of the Rho kinases. Fasudil showed a 
higher density of the blood vessels in comparison to the control, but the effect is not as strong 
as in the retinas of the H1152 injected mice. The retinas after being injected with Y27632, 
showed no differences in the density of the vascular network. However the network did show 
disruptions, which resulted in an incomplete and potentially non-functional network. 
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Figure 33: Retinas of H1152 and Fasudil injected mice showed a higher neovascularization in the isolectin 
staining whereas after an Y27632 injection the vascular network showed disruptions. (A) Control retina 
injected with DMSO. (B) Retina of a mouse injected with Fasudil. (C) Retina of a mouse injected with H1152. 
(D) Retina of a mouse injected with Y27632. 
 
Figure 34: Quantification of three pictures per group show more branching points in retinas from H1152 
and Fasudil injected mice whereas after Y27632 injection less branching points can be observed. The 
inhibition with Fasudil and H1152 increased the branching points (factor 3.61 respectively 6.99) whereas the 
inhibition with Y27632 led to a decreased number of branching points (factor 0.78). Mean values of three 
independent experiments are shown.  
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4.2. Inhibiton of Rho-dependent kinases in the myocardial 
infarction (MI) rat model  
 
Constitutive of the data in the OIR model, the hypothesis was developed that inhibition of 
ROCK I and II can activate angiogenesis in relation with cardiovascular diseases. A 
myocardial infarction study in rats was performed in cooperation with the working group of 
Prof. Henning (clinical pharmacology) at the Rijksuniversiteit Groningen, Netherlands. For 
this study the specific inhibitor of Rho kinases H1152 was used and the operations were done 
according to Zhao et al., 2009 (see also 2.2.5.3.2.). The myocardial infarction was performed 
by permanent ligation of the left coronary artery. Rats were anesthetized and the thorax was 
opened in the fourth intercostals space and the muscles overlying this region were dissected. 
Then the main left anterior coronary artery was ligated. With this ligation the myocardial 
infarction was induced and directly after the infarction the rats get an osmotic minipump in 
the neck. The rats were divided into three groups: (i) sham group (control I; n = 8), (ii) control 
group II (water; n = 16) and (iii) treatment group (H1152 (3 mg/kg/day); n = 16). 
 
 
4.2.1. Cardiac function measurements show no different levels between the 
different study-groups 
The rats were sacrificed seven days after the induced myocardial infarction. At this day the 
weight of the rats was higher than at the operation day (Figure 35A). Between the three study 
groups no differences in weight was observed. This indicates that all animals overcome the 
operation in the same positive way. In figure 35B two exemplarily hearts of rats are shown. It 
is clear to see, that below the ligation the tissue in the infarcted heart is much brighter than 
that in the sham heart. This means that a myocardial infarction was induced and the tissue is 
partly destroyed.  
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Figure 35: Rats weights and ligated hearts (A) Weight of the rats on the sacrificing day, seven days after the 
operation (sac. weight), is higher than on the day of the operation (OK weight). There is no difference between 
the study groups (delta weight); black: sham group (n = 8), grey: control group MI water (n = 16) and white: 
treatment group MI H1152 (n = 16). (B) Below the ligation (arrow) the destroyed tissue is brighter in the 
infarcted heart (right) than in comparison to the sham heart (left). 
 
 
Figure 36 shows that the measurements of the weights of heart, left kidney and right kidney 
differ insignificantly. The organ weights were normalized as the respective organ was divided 
by the body weight (Figure 36B). 
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Figure 36: The organ weights show no significant differences. (A) The weight of heart, left kidney and right 
kidney differ rarely between the study groups. (B) Organ weights were normalized to the body weight. The 
weight between the groups also differed rarely. hw/bw: heart weight divided by body weight. lkidw/bw: left 
kidney weight divided by body weight. rkidw/bw: right kidney weight divided by body weight. black: sham 
group (n = 8), grey: control group MI water (n = 16) and white: treatment group MI H1152 (n = 16). 
 
To investigate if the myocardial infarction has any influence on hemodynamic functions like 
blood flow or pressure multiple hemodynamic measurements were performed. These 
hemodynamic measurements showed only minimal differences between the three study 
groups as figure 37 shows. Additionally the aorta heart rate (Figure 37A) and the left ventricle 
heart rate (Figure 37C) were measured, as were the blood pressure (Figure 37B) and the 
systolic pressure of the left ventricle (Figure 37D).        
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Figure 37: Hemodynamic measurements seven days post operation show no significant differences 
between the study groups. (A) Heart rate (B.P.M.= beats per minute) (B) Aortic blood pressure (SBP = systolic 
blood pressure and DBP = diastolic blood pressure; mmHg = millimetre of mercury) (C) left ventricle heart rate 
(B.P.M.= beats per minute) (D) systolic pressure of the left ventricle (LVsys) and enddiastolic pressure of the 
left ventricle (LVEDP) (mmHg = millimetre of mercury. black: sham group (n = 8), grey: control group MI 
water (n = 16) and white: treatment group MI H1152 (n = 16). 
 
 
These experiments showed that the inhibition of Rho-dependent kinases with the inhibitor 
H1152 has no influence on the recovery of rats after an induced myocardial infarction. All 
measured parameters showed no significantly differences between the study groups. 
 
The literature dissociate between rats with a MI-size of more than 20% or less than 20%. The 
rats with a MI-size over 20% have been shown to develop heart failure. Table 2 showed the 
number of rats with a MI-size of more than 20% and the mean value. The body weight of the 
rats with the MI-size > 20% is lower in comparison to the sham heart. So one can clearly see 
that the rats with a bigger infarcted area recovery not in the same way than the sham animals. 
Also significant is the higher enddiastolic pressure of the left ventricle in the MI water group 
in comparison to the sham group. The enddiastolic pressure of the left ventricle is also higher 
in the MI H1152 group but this is not significant. 
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Table 2: Rats with a MI-size > 20% show differences in body weight and enddiastolic pressure of the left 
ventricle (LVEDP). Only animals with an MI-size > 20% were analysed. Increase in body weight was 14.5 g in 
the sham group and only 3.6 g in the MI water group and 7.0 g in the MI H1152 group. The LVEDP is higher in 
the MI water group (13.8 mmHg) and the MI H1152 group (11.5 mmHg) compared with the control (sham, 8.4 
mmHg) * P < 0.05 compared to sham. 
 
 sham MI water MI H1152 
Number 7 8 11 
MI-size [%] - 39.9 ± 4.9 34.93 ± 2.5 
Range MI-size [%]  23 - 61 23 - 46 
    
BW [g] 325.9 ± 7.2 313.3 ± 6.1 314.5 ± 3.2 
Increase in BW [g] 14.5 ± 2.7 3.6 ± 7* 7.0 ± 1.0 
    
Heart rate [mmHg] 362 ± 16 361 ± 7 348 ± 10 
SBP [mmHg] 111.7 ± 5.4 106.5 ± 3.5 102.6 ± 4.7 
LVEDP [mmHg] 8.4 ± 1.7 13.8 ± 1.8* 11.5 ± 1.4 
 
The results shown in table 2 indicate impaired cardiac functions like contractility and 
relaxation in rats with MI-size > 20%. Also the lower body weight of rats with myocardial 
infarction is a sign of impaired cardiac functions. 
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5. Discussion 
5.1. HOXA1 is a proangiogenic factor 
 
The expression of the transcription factor HOXA1 can be seen in the pharyngeal arch and 
brain regions in zebrafish (Thisse et al., 2005) and also in the neuroectoderm and mesoderm 
during hindbrain development in mice (Murphy and Hill, 1991), but not directly in endothelial 
cells. Chung et al. (2009) screened 37 HOX genes for changes in their expression patterns 
during differentiation of bone-marrow derived mesenchymal stem cells into endothelial cells. 
This screening identified angiogenesis-relevant HOX genes; e.g. the expression of HOXA7 
and HOXB3 was highly increased and the expression of HOXA3 and HOXB13 was strongly 
decreased during the process of differentiation (Chung et al., 2009). HOXB1, HOXB4, 
HOXB8 and HOXB9 were identified as being expressed in human umbilical vein endothelial 
cells (Belotti et al., 1997 and Belotti et al., 1998). The expression of HOXA1 in endothelial 
cells was clearly shown in this work. Immunocytochemical staining, Western Blot analyses 
and FACsorting showed that HOXA1 is expressed in human umbilical vein endothelial cells, 
bovine aortic endothelial cells and zebrafish endothelial cells, indicating a potential vascular 
function. 
Loss-of-function experiments were performed in vivo as well as in vitro as support for the role 
of HOXA1 in angiogenic processes. Loss-of-function experiments in vitro showed an 
inhibition of sprouting and migration. Possibly, the downregulation of HOXA1 leads to a 
decreased tube formation. HOXA1 silencing in zebrafish further supported these findings. 
The vascular network in the trunk was impaired and also the head vasculature was malformed 
resulting in cranial hemorrhages. Together all these results suggest a pro-angiogenic role of 
HOXA1. 
Interestingly, the basal and the stimulated migration as well as sprouting were reduced after 
HOXA1 siRNA-transfection to the same extent (see 3.3.1. and 3.3.2.) indicating that HOXA1 
signalling is not affected by the VEGF-pathway. This is also supported by the stimulation 
experiment. HOXA1 expression is not influenced by stimulation with growth factors like 
VEGF or FGF (see 3.3.5.). In several anti-tumour therapy strategies the VEGF-pathway is 
targeted and a variety of drugs base their concept on targeting this pathway (Palazzo et al., 
2010). The problem with this therapy concept is that there exists a VEGF resistance and so a 
number of studies have come out dealing with the development of VEGF independent targets 
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(Ferrara, 2010). The fact that HOXA1 is a positive regulator of angiogenesis independent of 
VEGF could be an advantage in developing anti-tumour therapies. 
The results showing that HOXA1 regulates angiogenesis fit together with other research 
findings in the field of HOX gene biology. Initially HOX genes were described as regulating 
morphogenesis, but many HOX genes are also able to regulate angiogenic processes (see also 
1.3.1.). HOXA9 promotes migration and also tube formation in endothelial cells (Bruhl et al., 
2004). HOXB2 was shown to be necessary for endothelial cell proliferation (Liu et al., 2004) 
and HOXD3 is active during tube formation of endothelial cells (Boudreau et al., 1997). 
These findings led to the consolidation of our hypothesis that HOXA1 can act as a pro-
angiogenic factor. 
5.2. E-selectin is regulated by HOXA1 in endothelial cells 
 
So far only some of the HOX transcription factors direct target genes are known. EPHB4 was 
identified as a direct target gene of HOXA9 (Bruhl et al., 2004), ß3-integrin is a target gene of 
HOXA10 (Daftary et al., 2002) and Flk1 is a target gene of HOXB5 (Wu et al., 2003). In this 
thesis a microarray was performed to identify possible HOXA1 target genes (see 3.4.). This 
microarray revealed E-selectin as a very promising HOXA1 target. With RT-PCR this result 
was proved and the experiment clearly showed that E-selectin is highly downregulated after 
HOXA1 downregulation. The fact that the cranial haemorrhages in zebrafish did not regress, 
implicates that wound healing would not be possible under HOXA1 silencing conditions. 
Furthermore E-selectin is known to play a crucial role during wound healing (Jubeli et al., 
2011), so it makes sense that E-selectin is not fully functional after HOXA1 silencing and 
thus head bleeding cannot regress. 
Another interesting point is that HOXA1 expression has been detected in human breast cancer 
lesions (Chariot and Castronovo, 1996). E-selectin is highly expressed in breast cancer tissue 
(Nguyen et al., 1997) which gives an indication of possible interactions between HOXA1 and 
E-selectin during breast cancer development. This leads to the perspective that the inhibition 
of either HOXA1 or E-selectin or both could stop breast cancer development. And it would be 
interesting to look on the other regulated genes from the microarray analysis. If there is 
another gene or genes which are also involved in breast cancer development, it would be 
interesting to look if there are interactions either with HOXA1 or E-selectin.  
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5.3. Further perspectives – HOXA1 
 
In this work, an influence on angiogenesis by HOXA1 was shown. Furthermore E-selectin 
was identified as a target gene of HOXA1. The interaction between HOXA1 and E-selectin 
needs further investigation. It will be important to investigate the expression of HOXA1 and 
E-selectin in different tumour phases, as the expression of both genes were shown in breast 
cancer tissue. Another interesting point to investigate would be HOXA1 and its target gene in 
the zebrafish model, as there is no homolog of E-selectin in the zebrafish. 
It would also be interesting to investigate other genes, which are regulated in the microarray 
(see 3.4.) e.g. CXCL2, PGF or CXCR4. The chemokine ligands and receptors could be 
especially interesting, because it’s known that HOXC9 regulates vascular development in an 
IL8 dependent way (Stoll et al., 2011). 
Taken together, this work offers new possibilities to understand angiogenic processes and 
suggests a new interaction pair: HOXA1 and E-selectin. This work also opens new 
perspectives in therapy of various diseases in which E-selectin is involved. 
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5.4. ROCK I/II functions as positive and negative regulators of 
angiogenic processes 
 
The analysis after the OIR model and H1152/Fasudil treatment showed that ROCK I/II 
inhibition leads to an increased neovascularisation in mouse retinas. Previous studies revealed 
that the inhibition of ROCK I/II, with pharmacological inhibitors, led to contradictory results. 
Different studies were performed with the inhibitor Y27632, where it was shown that even 
with the usage of the same concentration the results showed opposite effects. The inhibition of 
ROCK I/II with Y27632 enhanced migration and sprouting in the study of Mavria et al. 
(2006). Van Nieuw Amerongen et al. (2003) showed that the inhibition of ROCK I/II with 
Y27632 stunted migration and sprouting. In both studies 10 µM Y27632 was used for the 
experiments. The same circumstances can be seen in case of fasudil usage. One report by Yin 
et al. (2007) showed that usage of fasudil led to inhibition of angiogenesis, whereas the report 
by Nohria et al. (2006) described a positive impact on endothelial function after fasudil 
treatment. In our case, Y27632 showed no effect on retinal neovascularisation. 
A limiting factor of the inhibitors, are that these inhibitors do not distinguish between the two 
isoforms ROCK I and ROCK II. To generate conditional knock-out, it would be of interest to 
study the different functions of the isoforms on mice. 
In summary, this part of the project indicates that inhibition of ROCK I/II can promote and 
enhance respectively angiogenesis. In turn this implies that inhibition of the Rho kinases is a 
potential therapeutic target. 
5.5. ROCK I/II cannot act as therapeutic targets in cardiovascular 
diseases 
 
The myocardial infarction study implicates that the inhibition of ROCK I/II with the inhibitor 
H1152 has no positive impact on the recovery process after the infarct. The survival rate of 
the rats doesn’t differ between the study groups. Therefore, the inhibition of ROCK I/II with 
the inhibitor H1152 has neither a positive nor a negative effect on the survival rate. The 
measurement of the MI-size showed that the induced myocardial infarction was successful. 
This myocardial infarction induces angiogenesis at the border zone of the affected tissue. 
CD31 stainings showed this effect (data not shown), however it is an effect independent of 
H1152. Nevertheless, H1152 has no negative effect on angiogenesis. This study attested that 
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the inhibition of ROCK I/II with H1152 is not sufficient as a therapy after a myocardial 
infarction. 
5.7. Future perspectives – ROCK I/II 
 
In this part of the thesis, the impact of ROCK I and ROCK II in angiogenesis were shown. 
The results of the Isolectin staining in the OIR treated eyes showed that ROCK I and II are 
negative regulators of angiogenesis. This phenotype is similar to the observed phenotype from 
the Notch-signaling-pathway. If the Notch pathway is inhibited, an increased blood vessel 
formation can be observed (Siekmann and Lawson, 2007). For this reason, it would be 
interesting to concentrate further investigations on tip cell formation after ROCK I/II 
inhibition, as well as conducting NG2 staining to investigate pericyte coverage. 
In addition to the stainings mentioned in 5.6., an investigation on macrophages and eNOS 
could be of importance. Macrophages are involved in the development of VEGF, and eNOS 
plays an important role in the regulation of blood pressure and the functionality of blood 
vessels. Less activity or a dysfunction of eNOS promotes atherosclerosis. Another interesting 
point would be to analyse the level of ROCK I and ROCK II in different organs after the 
myocardial infarction, especially in the heart, and to analyse if H1152 regulates the level of 
the Rho kinases. 
Taken together, this part of the thesis shows some evidence that ROCK I/II are negative 
regulators of angiogenesis.  
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List of abbreviations 
 
A 
Ang   angiopoietin 
APS   ammonium persulfate  
 
B 
BAEC   bovine aortic endothelial cells 
bp   basepairs 
BSA   bovine serum albumin 
BTB    broad-complex, tramtrack and bric-a-brac 
BW   body weight 
 
C 
CaCl2   Calcium chloride 
CD31   cluster of differentiation 31 
cDNA   complementary DNA 
CIP   calf intestinal alkaline phosphatase 
cm   centimetre 
CO   carbon monoxide 
CO2    carbon dioxide 
CoCl2   Cobalt(II)chloride 
con   control 
CXCL   CXC ligand 
CXCR   CXC receptor 
 
 
D 
DAB    3,3'-Diaminobenzidine 
DAPI   4',6-diamidino-2-phenylindole 
Dfx   desferrioxamine mesylate 
DKFZ   Deutsches Krebsforschungszentrum 
DLAV   dorsal longitudinal anastomotic vessel 
Dll4   delta-like 4 
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DMEM  Dulbecco's modified eagle medium 
DMSO  dimethylsulfoxid 
DNA   deoxyribonucleic acid 
dNTP equal molar mix of the deoxy-nucleotides dATP, dCTP, dGTP and 
dTTP 
DTT  dithiothreitol 
 
E 
EC   endothelial cell(s) 
ECGM  endothelial cell growth medium 
ECL   enhanced chemoluminescence 
EDTA   ethylenediaminetetraacetic acid 
E. coli   Escherichia coli 
EGFP    enhanced green fluorescent protein 
eNOS   endothelium nitric oxide synthase 
EPC   endothelial progenitor cells 
Eph   ephrin receptor tyrosine kinase 
ERK    extracellular signal-regulated kinase 
et al.   and others  
Ets   E-twenty-six 
 
F 
FACS   fluorescence-activated cell sorting 
FAK   focal adhesion kinase 
FCS   foetal calf serum 
FGF (bFGF)  fibroblast growth factor (basic fibroblast growth factor) 
Fli1   friend leukemia virus integration 
Flk1   foetal liver kinase-1 
Flt   fms-like tyrosine kinase 
FOX   forkhead box transcription factor 
 
G 
g   gram 
GATA   G-A-T-A binding protein 
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GDP    guanosine diphosphate  
GEF    guanine exchange factor  
GFP   green fluorescent protein 
GTP    guanosine triphosphate  
GTPase   guanosine triphosphatase 
 
 
H 
h   hour(s) 
HCl   hydrochloric acid 
HIF    hypoxia-inducible factor 
hpf   hours post fertilization 
H2O2   hydrogen peroxide  
HRP   horse radish peroxidise 
HUVEC(s)  human umbilical vein endothelial cell(s) 
HOX   homeobox gene 
 
I 
Il1   interleukin 1 
iNOS   cytokine-inducible nitric oxide synthase 
ISV   intersomitic vessel 
 
K 
kb   kilobase 
KCl   kaliumchloride 
kDa   kilo Dalton 
KDR    kinase insert domain receptor 
kg   kilogram 
KLEIP   Kelch-like Ect-2 interacting protein 
 
L 
LB   lysogeny broth 
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M 
MCP-1  Monocyte chemotactic protein-1 
µg   microgram 
mg   milligram 
MI   myocardial infarction 
min   minutes 
ml   millilitre 
µl   micorlitre 
mm   millimetre 
µm   micrometre 
mM   millimolar 
µM   micromolar 
mmHg   millimetre of mercury 
MMP   matrix metalloproteinase 
Mo   morpholino 
MOI   multiplicity of infection 
mRNA  messenger ribonucleic acid 
 
N 
n   number of samples 
N2   nitrogen 
NaOH   sodium hydroxide 
NF-κB   nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
ng   nanogram 
nl   nanoliter 
nM    nanomolar 
NO   nitric oxide 
NP-40   Nonidet P-40 
Nrp   neuropilin 
 
O 
OIR   Oxygen-induced retinopathy 
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P 
P   p(probability)-value 
PCR    polymerase chain reaction 
PBS   phosphate buffered saline 
PBST   phosphate buffered saline with 0.1 % Tween 20 
PBSTT  phosphate buffered saline with 0.1 % Tween 20 and 0.1% Triton X 
PCR   polymerase chain reaction 
PFA   paraformaldehyde 
PGF   placental growth factor 
pH   pH value 
PH   pleckstrin homology  
pmol   pico-mol 
P/S   penicillin/streptomycin 
PTU   1-phenyl-2-thiourea  
 
R 
RAC   ras-related C3 botulinum toxin substrate 
RBD   Rho-binding domain 
Rho    ras homologous 
RNA   ribonucleic acid 
ROBO   roundabout 
ROCK   Rho-associated coiled-coil forming protein kinases 
rpm   rotations per minute 
RT   room temperature 
RT-PCR   reverse transcription PCR 
 
S 
SDS   sodium dodecyl sulphate  
SDS-PAGE  sodium dodecyl sulphate polyacrylamid gel electrophoresis 
sec   seconds 
siRNA   small interfering RNA 
SMC   smooth muscle cell(s) 
SOC   super optimal broth with glucose 
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T 
TAE   Tris base, acetic acid and EDTA 
TB   translational blocking 
TEMED  N, N, N', N'-tetramethylethylenediamine 
tg   transgenic 
Tie   tyrosine kinase with immunoglobulin and epidermal growth  
factor (EGF) homology domains 
TNF-α   tumour necrosis factor alpha 
Tris   Tris(hydroxymethyl)-aminomethan 
 
U 
U   Unit 
UTR   untranslated region 
 
V 
V   Volt 
VEGF   vascular endothelial growth factor 
 
°C   degree Celsius 
%   per cent 
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Appendix 
Overexpression of HOXA1 with adenovirus showed different 
results 
A HOXA1-adenovirus was prepared to analyse angiogenic processes like sprouting or 
migration in a HOXA1 overexpressed manner. The function of the adenovirus-construct was 
analysed in RT-PCR and Western Blot analyses. HUVEC was transduced with the adenovirus 
and lysed after an incubation period (see Material and Methods). After the RT-PCR, an 
upregulation of HOXA1 can be seen in the HOXA1 overexpressing samples. However, this 
upregulation is not very strong (Figure 38A). In the Western Blot analysis no regulation of 
HOXA1 was seen (Figure 38B). These results provoked the statement that the adenovirus is 
not functional. Mutations in the adenovirus-construct can be excluded because the sequence 
was checked several times. It could be possible that the protein structure of the adenovirus is 
folded in a different manner than the native protein. This could be the reason why, the 
HOXA1 antibody cannot bind to the HOXA1 adenovirus. Structural analysis, like 
crystallography, can help to clarify if the proteins are folded in a different way. 
Functional assays which were done with the HOXA1 adenovirus delivered positive results. In 
the sprouting assay, it was shown that after HOXA1 overexpression sprouting was highly 
increased (Figure 38C). On the other hand, the rescue experiment, where the cells were firstly 
treated with HOXA1 siRNA and then treated with the HOXA1 adenovirus, showed similar 
results to the experiments displaying overexpression (Figure 38C).  
To confirm the data from the microarray analysis, a RT-PCR with HOXA1 overexpressing 
cells was performed. In this experiment it can be seen that E-selectin is highly upregulated 
after HOXA1 overexpression. This fits together with the data of E-selectin regulation after 
HOXA1 downregulation (Figure 38D and also 3.4.1.). 
 
Appendix   
100 
 
 
Figure 38: Overexpression with adenovirus showed positve and negative results. (A) Agarose-Gel after RT-
PCR showed a higher HOXA1 expression after pAdHOXA1 transduction. (B) Western Blot analysis showed no 
difference in HOXA1 expression levels between pAdGFP and pAdHOXA1 transduced HUVEC. (C) 
pAdHOXA1 mediated upregulation increases in endothelial sprouting. The rescue-experiment looks similar to 
the experiment displaying overexpression. Mean values of three independent experiments are shown. (D) 
Agarose-Gel after RR-PCR showed that E-selectin is upregulated after HOXA1 upregulation. 
 
